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S U M M A R Y
This project was initiated following work performed within this Institute to produce 
antibodies against human growth homione for use in a serum immunoradiometric assay 
(IRMA) and some work to investigate the use of insulin like growth factor I (IGF-I) as 
a diagnostic and management tool for patients with particular growth disorders. 
Following initial attempts by other workers within the Institute to measure urinary 
growth hormone, it was concluded that an IRMA was unlikely to be capable o f  
providing adequate sensitivity for this application. This project was intended to 
investigate the possibility of using the available antibodies in a fluorimetric assay, using 
similar methodologies to those of Ishikawa et. al. (1987), (1988), to provide a sensitive 
assay for measuring urinary growth homione on a routine basis.
The production of a suitable antibody fragment from sheep polyclonal IgG was the first 
major hurdle in the project and it was not until this problem was successfully traversed, 
by the use of an alternative method to that of Ishikawa et. al. (1988), that it was 
possible to progress onto production of a peroxidase conjugate or to develop a working 
assay.
In the resulting assay, microtitration wells were used as an alternative separation system 
to polystyrene beads, for reasons of practicability. Initially a number of colourimetric 
peroxidase substrates were used in the optimization of the assay, and later when 
appropriate measuring equipment became available, fluorimetric and luminometric 
substrates were used in the hope of achieving enhanced sensitivity. The luminometric 
substrate,which was only investigated briefly at the last stage of the project, provided 
an assay with sensitivity in the range necessary for a urine growth hormone assay.
A number of problems were encountered when attempting to measure growth hormone 
in urine due to the presence of matrix effects, and attempts were made to eliminate these 
as far as possible from the assay. Hence a significant proportion of the work carried 
out involved investigating these matrix effects and showed that dialysis of the urine 
samples produced unsatisfactory results.
An assay was developed with the sensitivity required to measure growth hormone in 
urine but the matrix effects of urine samples on the assay could not be overcome 
adequately. Perhaps the realistic conclusion to be drawn is that a successful assay of 
this type requires investment in state of the art microtitre plate equipment, detection 
systems and the best available antibodies and enzyme labels. These are most likely to 
be provided by a commercial company with an international market for the product and 
the necessary financial backing.
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CHAPTER 1: INTRODUCTION
1.1 BA CK GROUND TO THE PROJECT
Growth hormone has been measured in serum, at the Institute o f  Biochemistry, 
Glasgow Royal Infirmary, for more than fifteen years. More recently insulin-like 
growth factor I (IGF-1) has been added to the list of available tests for the assessment 
of patients with abnormal secretion of growth hormone.
Recent publications have shown that measurement of growth hormone in urine is 
possible, despite the exceedingly low levels present. (Hashida et. al. 1985), (Girard 
et. al. 1990) There is accumulating evidence that measurement of growth hormone in 
urine may be useful in the diagnosis and management of acromegaly and Sheehans 
syndrome (Hashida et. a l l 987) and in the investigation of children with short stature 
(Tanaka et. al. 1990), (Okuno et. al. 1987), (Hibi et. al. 1987).
A number of monoclonal antibodies have been raised against human growth hormone, 
by the staff of the Institute of Biochemistry. Two of these antibodies have been 
successfully incorporated into the 'in house' immunoradiometric assay for serum 
growth hormone, which is in routine use in the Institute (Perry 1992).
This project was initiated with the intention of utilising these available antibodies to 
produce an assay for growth hormone in urine, based on the published method of 
Ishikawa et. al. (1988). The project would thus involve producing an enzyme- 
antibody fragment conjugate as an alternative label to radioisotopic antibody. This 
conjugate could then be used with either colourimetric or fluorimetric enzyme 
substrates in an attempt to maximise the signal to noise ratio, and so improve the 
minimum detection limit of the immunometric assay.
At the outset of this project, the production o f  antibody fragments and enzyme 
conjugates was a relatively unexplored technique within the Institute.
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1.2 G R O W T H  H O R M O N E
1.2.1 B iosynthesis  a n d  s t r u c tu r e
Growth hormone (somatotropin) is a single chain 191 amino acid polypeptide 
hormone (MW 21,500) which is synthesized and secreted by the somatotroph cells of 
the anterior pituitary. Growth hormone is produced by cleavage of the larger, 
physiologically inactive precursor, pre-growth hormone (MW 28,000) (Baulieu and 
Kelly 1990). There is heterogeneity of growth hormone structure in plasma (section 
1.2 .6)
Growth hormone and human placental lactogen have similar structures, having the 
same number of amino acids (161 of which are identical), and both having two 
disulphide bonds. Prolactin has some structural similarities but has an additional 
sequence of amino acids, being 199 amino acids in length, and has a third disulphide 
bond (Baulieu and Kelly 1990).
The genes corresponding to growth hormone, human placental lactogen and prolactin 
are thought to have evolved from a single precursor which subsequently diverged 
producing differences in structure and function of the hormones. Each of the genes 
contains distinct regulatory sequences. The genes for growth hormone and human 
placental lactogen exist as multiple copies which are closely linked on chromosome 
17, while prolactin exists as a single copy on chromosome 6.
1.2.2 F u n c t io n
Growth hormone has two major functions. The primary function is to promote linear 
growth while the secondary function is to influence carbohydrate metabolism.
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The carbohydrate and growth functions operate by different mechanisms and the 
majority of the growth promoting effects are mediated by a group of small peptides 
called som atom edins, which have m olecular weights of around 7.5 kD. 
Somatomedins are produced predominantly by the liver, but there is some production 
by cells from other sites. These peptides have structural similarities to proinsulin and 
are now known as insulin-like growth factors (IGF-I and II have been accepted). The 
insulin like growth factors circulate in plasma bound to specific high molecular weight 
binding proteins which may protect them from proteolysis, thus extending their half 
lives in p la sm a.
1.2.3 M echanism o f  action
The long term effects of growth homione on the growth of muscle and skeletal tissues 
are anabolic, and are mainly mediated by IGF-I, while the effects of growth hormone 
on carbohydrate metabolism and lipolysis are catabolic and opposed to those of 
insulin, these direct effects are mediated by receptors within the target tissue (Table 
1.2.1) (Baulieu and Kelly 1990).
The action of growth hormone on its target organ involves the binding of the hormone 
to specific receptors located on the plasma membrane of the target cell. The existence 
of receptors in humans for growth hormone has been shown in a number of tissues 
including the liver and lymphocytes (Hughes et. al. 1985).
The growth hormone receptor was thought to be a monomeric glycoprotein with a 
molecular weight of around 130 kD, which spans the plasma membrane. More 
recently the structure of the rabbit growth hormone receptor has been determined by 
purification of the receptor from liver and partial amino acid sequencing (Leung et.al. 
1987). The receptor consists of 638 amino acids divided almost equally into 
intracellular and extracellular domains by 24 hydrophobic amino acids which are likely 
to provide the transmembrane domain. The extracellular domain contains an identical
Table 1.2.1 Effects of growth hormone on the major sites of action.
(Adapted from Baulieu and Kelly 1990.)
Action of Growth Hormone T is su e
Direct action
IGF-I production Liver and fibroblasts (in culture)
Protein synthesis Liver
Amino acid transport Liver, muscle, and adipose tissue
Lipolysis Adipose tissue
Carbohydrate metabolism 
(hyperglycaemia)
Liver
Indirect action (via IGF)
Chondrogenesis Cartilage
Skeletal growth Bone
Protein synthesis Soft tissues
General cell growth
N terminal amino acid sequence to that of growth hormone binding protein isolated 
from serum. The 18 amino acids which precede the N terminal sequence form the 
signal peptide (Thomer et. al. 1993). Rabbit cDNA clones have been used to examine 
a human cDNA library to identify similar clones of the human growth hormone 
receptor. The rabbit and human receptors have 84% amino acid homology. The 
receptor has a molecular size of 70 kD, smaller than the 130 kD receptor originally 
isolated, mainly due to glycosylation. The amino acid sequence of the receptor for 
prolactin has been shown to have homology with the growth hormone receptor 
(Boutin et. al. 1988), (Baulieu and Kelly 1990), (Thorner et. al. 1993). The number 
of these receptors increase following puberty, during pregnancy and lactation (Kelly 
et. al. 1974). The receptors may be up or down regulated depending on the levels of 
hormone acting on the receptors. The binding of growth hormone to the receptor 
stimulates protein synthesis.
Receptors have been identified for IGF-I and II, the first preferentially binds IGF-I 
and has weak affinity for insulin, while the second preferentially binds IGF-II and has 
no affinity for insulin (Baulieu and Kelly 1990). The IGF-I receptor is structurally 
similar to the insulin receptor. Administration of IGF-I to hypophysectomised rats has 
a direct effect on stimulation of body weight increase, hypophyseal cartilage width, 
and DNA synthesis in cartilage (Schoenle et. al. 1982).
Serum concentrations of IGF-I rise steadily during childhood, from a low point at 
birth to the start of puberty, at which time there is a large increase in concentration 
which then falls gradually during adulthood (Baulieu and Kelly 1990).
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In the liver cell growth hormone stimulates IGF-I production and directly increases the 
rate of cell replication and the mechanisms of protein synthesis including increased 
uptake of amino acids and acceleration of transcription and translation o f  mRNA 
(Baulieu and Kelly 1990).
The rate of protein catabolism is also reduced in response to growth hormone by 
stimulating lipolysis and therefore utilising fat as an alternative source of energy. 
Fatty acids are released from adipose tissue and converted by (3 oxidation to acetyl- 
CoA which is then available as a source of energy via the Krebs Cycle .
Carbohydrate metabolism is moderated in response to growth hormone release, with 
reduced glucose uptake by cells due to impairment of insulin action. There is a 
resulting increase in insulin secretion in response to the increased plasma glucose 
concentration.
1.2.4 Control o f  secretion
There are two neurohormones produced by the hypothalamus which continuously 
adjust the level of growth hormone secretion. Growth hormone releasing hormone 
(GHRFI) is a 44 amino acid peptide which specifically stimulates growth hormone 
secretion. Somatostatin specifically inhibits growth hormone secretion. (Figure 1.2.1) 
Somatostatin exists as both a 14 amino acid form and as a 28 amino acid form, with 
the additional amino acids on the N terminal end (Baulieu and Kelly 1990).
Figure 1.2.1
Primary mechanism of control of growth hormone secretion
(Adapted from Baulieu and Kelly 1990)
sleep
stress
exercise
drugs
hypothalamus
GHRH somatostatin
somatotropic cell of 
anterior pituitary
— growth hormone
liver cell
-  IGF I
Indirect action of 
growth hormone 
leading to 
anabolic effects
Direct action of 
growth hormone 
leading to 
catabolic effects
Peripheral effects
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There are specific receptors for GHRH on the somatotropic cells of the anterior 
pituitary. These respond to GHRH by increasing production of cyclic adenosine 
monophosphate (cAMP). Somatostatin acts on the somatotropic cells inhibiting cAMP 
production, but it is likely that there are other modes of inhibiting growth hormone 
secretion, which are also affected by somatostatin (Baulieu and Kelly 1990).
A variety of other factors also affect growth hormone secretion (Table 1.2.2). These 
include several hormones; thyroid hormones, glucocorticosteroids, oestrogens, and 
androgens (Baulieu and Kelly 1990), (Thorner et. al. 1993).
The secretion of growth hormone over a 24 hour period is pulsatile (Veldhuis et. 
al. 1988). This pattern of secretion is mainly due to the influences of somatostatin and 
GHRH, under the control of higher centres. The circadian rhythms of release of these 
two hormones are out of phase. Therefore when the level of somatostatin falls, and 
GHRH rises, there is a peak in growth hormone secretion.
One of the major growth hormone peaks occurs during the night (Rudd 1991). There 
are additional minor peaks associated with sleep. In children and young adults a 
growth hormone pulse occurs after around one hour of deep sleep followed by 
subsequent peaks during the sleep cycle. The increased secretion of growth hormone 
during sleep may be due to stimulation by falling levels of free fatty acids. This may 
also account for the decreased levels of growth hormone found in obese patients 
(Baulieu and Kelly 1990) (Griffen 1991).
IGF-I has an inhibitory effect on growth hormone production by means of a negative 
feedback loop which acts on the anterior pituitary and on the hypothalamus (Baulieu 
and Kelly 1990).
Table 1.2.2 Factors affecting growth horm one secretion .
(Adapted from Frohman 1981)
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Increase in growth horm one D ecrease in growth horm one
P h y s io lo g ic a l
sleep
exercise
stress (physical or psychological) 
postprandial: 
hyperaminoacidaemia 
hypoglycaemia (relative)
postprandial hyperglycaemia 
elevated free fatty acids
P h arm acolog ica l
hypoglycaemia 
absolute: post glucagon or 
2-deoxyglucose 
relative: post glucagon
hormones:
GHRH
peptides (ACTH, a-M SH, vasopressin) 
oestrogen
neurotransmitters, etc:
a  adrenergic agonists (clonidine)
(3 adrenergic antagonists (propanolol) 
serotonin precursors 
dopamine agonists (levodopa, 
apomorphine, bromocriptine)
GABA agonists (muscimol)
pyrogens {Pseudomonas endotoxin)
hormones: 
somatostatin 
growth hormone 
progesterone 
glucocorticoids
neurotransmitters, etc.:
a  adrenergic antagonists(phentolamine)
(3 adrenergic agonists (isoproterenol) 
serotonin antagonists (methysergide) 
dopamine antagonists (phenothiazines)
P ath o log ica l
protein depletion and starvation
anorexia nervosa
ectopic GHRH production
chronic renal failure
acromegaly
TRH
GnRH
obesity
acromegaly: dopamine agonists 
hypo and hyperthyroidism
Growth hormone secretion is stimulated by stress and exercise, and is subject to 
changes in nutritional status. Hyperglycaemia prevents the growth hormone release 
due to stress in normal individuals, but is not effective in diabetics (Buchanan 1987).
Thus in summary it is clear that the pattern of growth hormone release is complex due 
to a variety of different influences. The basic circadian rhythm of release is enhanced 
during the night by the effects of sleep, reduced during the day following meals and 
increased following periods of exercise (Figure 1.2.2)
1.2.5 D istribution and peripheral m etabolism
Following secretion from the pituitary growth hormone is distributed within a 
compartment whose volume is intermediate between the intravascular space and the 
intracellular space.
A binding protein for growth hormone has recently been identified which complexes a 
major portion of circulating growth hormone. The biological function of this protein is 
as yet unknown. The complexed growth hormone is restricted to the intravascular 
space to a greater extent than growth hormone, and the volume of distribution is more 
limited, this reduces the clearance of bound growth hormone by the kidneys, and may 
prolong the plasma half life (Baumann et. al. 1986), (Baumann et. al. 1987) 
(Baumann 1988).
The confinement of complexed growth hormone to the intravascular space may 
prevent glomerular filtration by the kidneys and explain why growth hormone, which 
is readily filtered by the glomerulus, does not appear in large quantities in urine 
(Baumann et. al. 1987).
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F igu re 1.2.2
Typical adult 24 hour growth horm one profile  
(G riffin  1991)
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A concentration gradient for growth hormone exists between plasma and tissue fluid. 
There is a resulting increase in the volume of distribution of growth hormone in 
conditions which cause increased capillary permeability such as hepatic failure, renal 
failure, and uncontrolled diabetes (Owens et. al. 1973).
The metabolism of growth hormone is carried out by the liver and the kidneys in 
approximately equal proportions (McCormick et. al. 1969). The fractional clearance of 
growth hormone from these sites is unaffected by differences in plasma concentrations 
(Owens et. al. 1973). Metabolism of growth hormone by the liver may be due to 
receptor mediated cellular uptake and degradation by lysosomes (Baumann et. al. 
1987).
Growth hormone metabolism is reduced in renal failure and myxodema but is little 
affected in liver disease (Owens et. al. 1973).
1.2.6 H eterogeneity o f hum an growth horm one
Growth hormone exists in plasma in more than one form and this heterogeneity may 
cause discrepancies between assays using different antibodies and create problems of 
interpretation (Table 1.2.3). The physiological significance of these different forms of 
growth hormone is unclear but they may be relevant where the levels of growth 
hormone, measured by immunoassay, do not agree with the clinical picture due to the 
presence of circulating immunoreactive but bio-inactive forms (Smith et. al. 1990).
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T able 1.2.3 M ajor form s of growth horm one found in serum .
(Smith et. al. 1990).
Variant A pprox. MW  
(kd)
Com m ents
Monomeric pituitary HGH 22 Approx 75% total immunoreactive HGH
HGHiOkd 20 Approx 16% total immunoreactive HGH
’Big' HGH 40-50 Dimers
’Big-big’ HGH >60 (a) Aggregates
(b) HGH binding protein complex
Fragments <20 Present in serum in basal state
May be formed in tissues.
Placental HGH 22 Secreted by placenta
24,26 Glycosylated forms of placental HGH
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Molecular heterogeneity may affect immunoassays for growth hormone since the sites 
to which the antibodies bind may be on different regions of the molecule to the 
physiological binding site. It is therefore possible that any immunoassay may detect 
inactive fragments or aggregates of the hormone. In addition the purified or synthetic 
hormone used to raise the antibodies is generally in an unmodified monomeric form 
and therefore an assay may not detect modified forms which have biological activity 
(Smith et. al. 1990) (Rudd 1991).
1.2.7 Excretion of growth horm one into urine
Despite the fact that the kidneys account for half the growth hormone metabolism, the 
majority o f  this undergoes proteolysis and the amount of growth hormone excreted 
unchanged by the kidneys is very small (<0.001 % of production), the concentrations 
in urine are therefore normally very low (Girard et. al. 1990) (Okuno et. al. 1987).
3 5
1.3 IN D IC A T IO N S  FO R  M E A S U R E M E N T  O F  G R O W T H  H O R M O N E
1.3.1 U sefulness of basal s e ru m  g ro w th  h o rm o n e  m e a su re m e n t
Due to the pulsatile nature of growth hormone release and its short plasma half life 
growth hormone concentrations in adults and in children may be very low and random 
determination of the serum growth hormone level is of little value in the assessment of 
growth hormone status (Hashida et. al. 1985).
A number of provocation tests have been used to determine the ability to produce 
growth hormone in response to physiological or pharmacological stimuli (Table
1.3.1). The exercise test, the nocturnal profile, oral clonidine and the insulin tolerance 
test, are the most commonly used in Great Britain at present. Great care is required in 
performing these tests to ensure standard conditions are maintained. The nocturnal 
profile is particularly difficult and labour intensive to perform (Buchanan 1987).
1.3.2 G ro w th  h o rm o n e  defic iency
There are a variety of conditions which cause short stature most of which are growth 
hormone independent (Table 1.3.2). It is therefore important to measure growth 
hormone as part of the assessment of short stature to distinguish those children who 
may be aided by growth hormone therapy from those who are not growth hormone 
deficient (Table 1.3.3). There are a number of causes of growth hormone deficiency 
which may be congenital acquired or which may only be transient sequelae of another 
condition (Table 1.3.4).
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T ab le  1.3.1 G ro w th  h o rm o n e  p rov o ca t io n  tests
(Adapted from Buchanan 1987)
Test Protocol
Post-prandial Samples 3 and 4 hours post ingestion of 
glucose (1.4 mg /  kg) or high 
carbohydrate meal
Post exercise Samples pre and 30 minutes post 
strenuous exercise (15 minute walk or 
running up and down stairs for 5 
minutes)
Nocturnal profile regular samples prior to and after the 
onset of sleep
Arginine infusion Intravenous arginine HC1 10 % 
administered for 30 minutes and samples 
taken at times 0, 30 ,60 ,90, 120 minutes
Glucagon Intramuscular glucagon (100 mg /  M2 
max 1 mg) administered and samples 
collected at 30 minute intervals for 3 
hours
Oral clonidine Oral clonidine (0.1 mg /  M2) and samples 
are taken at 0, 30, 60, 90,120 minutes
Insulin tolerance test Intravenous insulin (0.1-0.15 U/kg) 
administered and samples for glucose and 
growth hormone taken at 0, 30, 45, 60, 
90, 120 minutes
T able 1.3.2 C auses o f short stature
(Adapted from Buchanan 1987)
Congenital
H ereditary
Laron dwarfism 
Turner’s syndrome 
Primary hypothyroidism 
Congenital cardiac disease 
Growth hormone deficiency
D evelopm ent defects
Constitutional delay in growth and puberty 
Familial short stature
Chronic gastro intestinal disease eg.Crohns disease, coeliac disease 
Intrauterine growth retardation eg. foetal alcohol syndrome 
Skeletal dysplasia
Acquired
Chronic renal disease 
Diabetes mellitus 
Chronic systemic disorders
Glucocorticoid excess eg. Cushings syndrome, adrenal tumour
Transient
Nutritional insufficiency eg. protein malnutrition 
Psychosocial deprivation
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Table 1.3.3 A ssessm ent of child with short stature
(Adapted fom Buchanan 1987)
M edical and social history
A nthropom etry
Child's height and weight 
Estimation of child's rate of growth 
Parental height
Physical exam ination
Bone age
Karyotype to exclude Turners syndrome in females
O ther relevant investigations
Haematological
Biochemical
Endocrine
Cardiac
Renal
Gastrointestinal
Skeletal
T able 1.3.4 Causes of growth horm one deficiency
(Adapted from Buchanan 1987)
Congenital
H ereditary
Autosomal recessive 
Autosomal dominant
Idiopathic growth hormone releasing hormone deficiency
D evelopm ent defects
Pituitary aplasia 
Pituitary hypoplasia 
Midline anomalies
Acquired
Tum our
Hypothalamic
Pituitary
Other intracranial 
Irradiation  
In fection
Meningitis
Encephalitis
In filtration
Histiocytosis 
H aemac h ro m a to s i s
Injury
Perinatal insult 
Head injury
Transient
Peripubertal
Psychosocial
Primary hypothyroidism
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1.3.3 G ro w th  h o rm o n e  excess
Hypersecretion of growth hormone from a pituitary adenoma in adults produces 
acromegaly, whereas in adolescents if hypersecretion occurs before the closure of the 
epiphyses of the long bones, the result is acromegalo-gigantism. In addition there are 
rare examples of ectopic growth hormone production and pancreatic GHRH releasing 
tumours (Baulieu and Kelly 1990).
IGF-I is raised in acromegaly and it may be a more useful marker of excessive growth 
hormone production than growth hormone itself since growth hormone concentrations 
can fall within the upper part of the reference range, whereas IGF-I is almost always 
raised (Baulieu and Kelly 1990), (Thorneret. al. 1993). Glucose tolerance is reduced 
by around 50% in acromegaly and approximately 10% of patients are diabetic. 
Acromegaly can be treated by using neurosurgery to remove microadenomas by 
irradiation of the tumour or with bromocriptine or pergolide which are dopamine 
agonists. An alternative medical treatment for patients who do not respond to the 
above therapies is to use long acting synthetic analogs of somatostatin, such as 
Octreotide, to suppress growth hormone production by the pituitary (Harris 1990), 
(Liuzzi et. al. 1990), (Sassolas et. al. 1990).
1.3.4 U rine  g row th  h o rm o n e  m e a su re m e n t
It has been shown that concentrations of growth hormone in nocturnal urine, when 
corrected for renal function, correlate with the corresponding mean serum growth 
hormone, serum IGF-I and urine IGF-I measurements over the period o f  urine 
collection (Tanaka et. al. 1990) (Okuna et. al. 1987) (Sukegawa et. al. 1988) (Quattrin 
et. al. 1988). This can be a useful tool in distinguishing excessive from normal growth 
hormone production in acromegaly although the overlap between normal reduced and 
deficient production is more difficult to resolve (Kohno et. al. 1990). Urine growth
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hormone measurement is useful for monitoring growth hormone secretion but cannot 
be used to follow the pattern of pulsatile release (Girard et. al. 1990).
There could be considerable benefits to be gained from the use of a simple urine 
screening test in preference to the more invasive stimulation tests described above 
which cany their own inherent risks to the child (Table 1.3.1). Not the least of these is 
the advantage of not having to subject children to such testing where a simple early 
morning urine or timed specimen can be collected.
1.3.5 Treatm ent with recom binant growth horm one
Growth hormone is a species specific hormone and this prevents the use of animal 
derived hormone in treatment. Since 1958 (Raben 1958) cadaveric human growth 
hormone has been used in limited amounts in replacement therapy. This treatment 
ceased in the UK following the occurance of Creutzfeldt-Jakob disease in some 
patients receiving treatment with the relatively impure preparations of cadaveric growth 
hormone (Buchanan 1987).
The first biosynthetic growth hormone, Somatrem, was given a product licence in 
1985, this and other synthetic preparations have since been used in treatment of 
growth hormone deficiency (Buchanan 1987). The greater availability of growth 
hormone has now led to it’s contentious use in short children who are not necessarily 
growth hormone deficient and in adults who are growth hormone deficient or are 
elderly.
1.4 METHODS FOR GROWTH HORMONE MEASUREMENT
1.4.1 Bioassay for growth hormone
Early assays for growth hormone depended on quantification o f its biological activity 
using for example the effect of injected growth hormone on increasing the width o f the 
epiphyseal tibia cartilage of rats (Greenspan et. al. 1949).
Subsequently specific radioreceptor assays were developed where 125I labelled human 
growth hormone competes with the unlabelled growth hormone for binding to human 
cultured lymphocytes (Lesniak et.al. 1973) (Gavin et. al. 1982) (Tanaka et. al. 1983).
With the introduction o f  radioimmunoassays the use o f antibodies allowed  
measurements which were dependent on the three dimensional structure o f the 
hormone. The presence o f heterogeneous forms o f growth hormone with different 
activities as well as inactive fragments, can provide misleading information in structure 
specific assays. However although it is the biological activity o f growth hormone 
which is o f clinical interest, function specific assays are time consuming and 
unsuitable for large scale laboratory use and immunoassays have become firmly 
established.
1.4.2 Early radioimmunoassay for growth hormone
A radioimmunoelectrophoretic assay for human growth hormone using 131I was first 
published in 1964 by Hunter and Greenwood. In this method 10 ml o f plasma was 
first extracted with acetic acid-acetone and then a radioimmunoassay was performed 
using rabbit antibody with an 8 to 12 day incubation followed by separation of bound 
from free growth hormone using electrophoresis. Due to the 8 day half life o f 131I, 
growth hormone was iodinated using chloramine T each w eek (Hunter and 
Greenwood 1962), (Greenwood and Hunter 1963).
During the following two decades improvements in reagents, coupled with a greater 
understanding of immunoassay design led to the evolution of radioimmunoassays for 
serum growth hormone based on much smaller specimen volumes (typically 100 p.1) 
and on a much shorter turn around time (typically 36 hours). Assays for serum 
growth hormone became firmly established in most regional endocrine laboratories. 
By preparing and distributing carefully matched reagents the Edinburgh group were 
able to demonstrate dramatic improvements in in ter-laboratory performance of growth 
hormone radioimmunoassays which in turn led to consensus action limits for clinical 
practice (Hunter et. al. 1978).
1.4.3 Two site im m im om etric assays for growth horm one
A method of labelling anti-growth hormone antibody with was published by 
Miles and Hales in 1968 and this was used in a one site immunometric assay. Growth 
hormone was attached to a cellulose-based immunoabsorbent and incubated with 
labelled antibody and free growth hormone. After separation, the amount of labelled 
antibody which was bound to the immobilised growth hormone provided a measure 
of the amount of free growth hormone in the sample.
A two site IRMA or sandwich assay was developed by Addison and Hales in 1971. 
In this method the antigen is sandwiched between a labelled antibody and a solid phase 
coupled antibody.
The most sensitive systems being those where labelled antibody is added first:
*Ab+Ag - = — *Ab-Ag
followed by addition of solid phase coupled antibody:
*Ab-Ag+Absoiid = = -  *Ab-Ag-Abs()| id 
(Hunter 1982)
1.4.4 C urrent status of two site iinm unom etric assays for serum  growth
horm one
Unlike TSH there has been only a limited number o f  attempts to develop 
immunoassays for growth hormone and growth hormone IRM A’s have been relatively 
slow to appear. This may be due to the smaller demand for growth hormone kits. 
From the UK external quality assessment scheme reports of December 1991 there 
were three suppliers of serum growth hormone IRMA's with five or more users: IDS 
OMNIA, NETRIA IRMA (North East Thames Radio Immunoassays), and Pharmacia 
IRMA. The IDS assay was developed within this Institute and is based on a labelled 
monoclonal antibody and polyclonal antibody linked solid phase. The NETRIA 
assays similarly uses a monoclonal label and a polyclonal linked solid phase.
1.4.5 M ethods used for urinary growth horm one
Since the assay of growth hormone in urine requires sensitivity in excess o f  one 
hundred times that of the corresponding serum assay, non-specific interference from 
pH, osmolarity and urea concentration must be minimised. In addition high avidity 
antisera are essential as is the sensitivity provided by antibody excess immunometric 
assays (Girard et. al. 1990).
Sample collection and preparation must be carefully considered, some assays use 
albumin to prevent adsorption of growth hormone onto the surface of the urine 
collection container. Other assays involve dialysis of the urine to remove interfering 
salts while less sensitive assays concentrate urine samples before analysis (Table
1.4.1).
The incubation times of antibodies with the antigen are generally extended to allow 
maximum binding and the highest sensitivity possible, for example one assay uses a 
44 hour incubation with the secondary antibody (Girard et. al. 1990).
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Since growth hormone excretion may be affected by decreased renal function, growth 
hormone concentrations are generally expressed with reference to the corresponding 
creatinine concentration.
1.5 DESIG N OF AN ASSAY FOR URINARY GROW TH HO RM ONE
1.5.1 O b jectives
Any assay for urinary growth hormone faces two major difficulties from the outset. 
Firstly growth hormone is only present in urine in quantities below the minimum 
detection limit of most immunoradiometric assays. This means that either a highly 
sensitive non-isotopic assay is required (sensitivity of 0.006 mU/1 (3 ng/1)), or that the 
samples must be concentrated prior to analysis (Hashida et. al. 1986). Concentration 
of large numbers of urine samples by a quantitative method is time consuming and 
would be unsuitable for routine use. The second major hurdle in measuring growth 
hormone in urine is the interference from salts which may be present at widely varying 
concentrations in urine. In a number of the published assays for urinary growth 
hormone, this problem has been solved by dialysing the urine samples in buffer, 
before analysis (Evans and Wood 1989) (Girard et. al. 1990). Whilst successful, this 
is a laborious task and unworkable on a large scale.
With these facts in mind, the objectives in designing an assay for growth hormone in 
urine were:
a) The assay should be capable of measuring growth hormone with a sensitivity
of 0.006 mU/1. If possible sample concentration should be avoided.
b) The assay should not be subject to interference from different urine matrices.
c) The assay should be suitable for routine use in a busy department, and should
be robust.
1.5.2 Im m unoassay types and com ponents
Immunoassays can be classified according to whether they involve:
1 Limited reagent or reagent excess
2 Separation of antigen bound to antibody from free antigen or non separation
3 Isotopic or non-isotopic labels
1.5.2.1 Lim ited reagent and reagent excess assays
The assay design chosen for an application depends on the particular nature of the 
analyte. Small molecular weight antigens are unlikely to be large enough to have more 
than one distinct antibody binding site and therefore a limited reagent (competitive) 
assay is most suitable (Hunter 1982). Where a minimal detection limit is essential, a 
reagent excess assay (sandwich assay) is more suitable as this is less dependant on the 
precision of reagent addition (Price et. al. 1991).
In these immunometric assays, one of the antibodies can be coated or attached 
chemically to the surface of microtitre wells to provide the separation system. The 
second antibody may be labelled with ]~5I, an enzyme, or with a lanthanide chelate 
such as europium, and provides the detection system for the assay. These reagent 
excess assays use quantities of antibodies which do not act as a limiting factor on 
antigen binding.
1.5.2.2 Separation  and non-separation  assays
Heterogeneous assays are assays which include a separation stage to remove the 
antibody bound antigen from the unbound antigen. In the case of homogeneous 
assays, the detection system allows the presence of both the bound and free fractions 
without interference. Heterogeneous assays tend to have lower detection limits and be 
subject to less interference from sample components. (Price et. al. 1991) These are
desirable factors in the analysis of growth hormone in urine. Homogeneous assays 
generally have less steps and are simpler to perform and to automate than 
heterogeneous assays and are used in for example therapeutic drug analysis.
In microtitre plate assays, separation is achieved by coating one antibody onto the 
surface of the wells, to which the antigen binds, allowing the removal of the unwanted 
sample components by repeated washing using an automated washing device.
1.5.2.3 Isotopic and non-isotopic labels
Isotopic labels have been used extensively, as in most cases incorporation of 125I into 
small molecules and into antibodies is relatively simple. There are disadvantages in 
the limitations on the handling and disposal of radio-isotopes and the short half life of 
some of the isotopes. The limited signal to noise ratio of 125I is unlikely to provide a 
detection limit which is adequate for use in a urinary growth hormone assay.
An immunochemiluminometric assay for serum growth hormone using antibodies 
produced within this institute has been published by Weeks and Woodhead (1986). 
This assay uses acridium ester labelled monoclonal antibodies and a polyclonal 
antibody attached to magnetisable solid phase particles. The reported sensitivity is 
0.12 mU/1 and the working range is 0.88 to over 100 mU/1.
A lanthanide chelate of europium has been used in this institute as an alternative 
isotope for measuring human growth hormone. This DELFIA (Dissociation- 
Enhanced Lanthanide Fluoroimmunoassay) assay may potentially have a signal to 
noise ratio large enough to produce the low detection limit required for measuring 
growth hormone in urine.
The use of an enzyme-antibody fragment conjugate as an alternative label, coupled 
with an appropriate fluorimetric substrate, may provide a large signal amplification and
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low background counts, and an assay suitable for urinary growth hormone 
measurement (Hashida et. al. 1986).
1.5.3 Production of antibody fragm ents
A single IgG molecule is composed of two heavy chains and two light chains which 
are linked by the thiol groups of the amino acid cystine (Figure 1.5.1). These bonds 
can be broken by reduction  with com pounds such as m ercap toethanol,  
mercaptoethylamine, iodoacetamide, or dithiothreitol.
IgG can also be cleaved by using the protease pepsin, leaving the fragments F(ab')2 ,
Fc and, pFc (Figure 1.5.1). The F(ab')2 fragments produced can be reduced to Fab' 
fragments, as above. The Fab' fragments, thus produced, retain the hinge region and 
the thiol groups. In contrast papain cleaves the IgG molecule above the hinge region 
producing two Fab' fragments, which lack thiol groups, and an Fc fragment.
1.5.4 Preparation o f Fab'-enzvm e conjugates
As mentioned in the previous paragraph pepsin digestion of IgG followed by 
reduction with mercaptoethanol leaves an Fab' fragment which retains the hinge region 
and the thiol groups of cysteine. This allows an enzyme molecule to be linked, by 
heterobifunctional reagents, to an Fab' fragment (Figure 1.5.2). This process requires 
two steps and uses a linking group such as maleimide with two different arms, one of 
which attaches to the enzyme, and one of which attaches to the thiol group of the Fab' 
fragment (Figure 1.5.3).
In step one the enzyme is mixed with excess linking reagent, allowing maximum 
binding to the enzyme. In step two the excess linking reagent is removed and Fab' 
fragment is added to allow conjugate formation. Finally the conjugates are separated
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Figure 1.5.1
Illustration of IgG showing the cleavage points of pepsin, papain 
and mercaptoethylamine.
N terminal end
C terminal end
Fab'papain
hinge
mercaptoethylamine split
pepsin pepsin
light chain 
heavy chain 
 IU  L
pFc Fc F(ab')2
Figure 1.5.2
Production of an enzyme-Fab' conjugate by the hinge method
IgG
Cleavage of IgG by pepsin
F(ab’)2
Reduction of F(ab')2 with mercaptoethylamine
Conjugation of Fab' with peroxidase-maleimide
O
N H — C —R—Nperoxidase
Omaleimide
Peroxidase Fab' conjugate.
Figure 1.5.3
The two step maleimide method for enzyme labelling Fab’ fragments, 
(hinge method)
Using the two step maleimide method for enzyme labelling o f Fab' 
fragments the reaction products are more predictable than one step methods 
and the conditions for each step may be optimised to improve the yield of  
conjugate. (Adapted from Ishikawa et. al. 1988)
(^peroxidase^)— NH2
step 1 Add maleimide linking reagent
O
(^peroxidase^)— ]
O
A
N H —C —R—NY
O
N —O — C —R—N
step 2 Add Fab' 
fragment o f IgG
(peroxidase
—
■NH—C —R—N
O
Peroxidase -Fab' conjugate.
The R group o f the linking reagent may be either: 
-(CH2)5-
N-succinimidyl-6-maleimidohexanoate
or
N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-l-carboxylate
from any unbound Fab1 fragments. Reaction conditions, at each step, can be adjusted 
to optimize linking (Ishikawa et. al. 1983).
It is also possible to link Fab fragments from papain digestion o f IgG, to enzymes 
such as peroxidase, P -D -galactosidase, or alkaline phosphatase, using  
homobifunctional linking reagents such as glutaraldehyde (Avrameas 1969), 
(Avrameas et al. 1978). This conjugation may be performed as a one step process by 
incubating glutaraldehyde with Fab fragment and enzyme. (Figure 1.5.4) However 
since the rates o f reaction o f the functional groups on the Fab fragment and enzyme are 
likely to be different, the reaction may favour polymerisation o f either the Fab 
fragment or the enzyme in preference to Fab-enzyme conjugate formation.
1.5.5 Enzymes as labels in immunoassays
Enzymes have a number of advantages over radioactive labels in immunoassays (Price 
et. al. 1991). In the particular application o f urine growth hormone, the stability of the 
reagents is an important advantage since monthly iodinations are acceptable, where the 
assay is carried out several times a week, but where the workload is lower, and the 
assay is only being performed once or twice a month, the time required for iodination 
and purification o f the label is unacceptable. The time taken to produce an enzyme 
conjugate is longer than for an iodine label, but producing an enzyme label once a year 
saves time and gives a more consistent reagent. The use o f enzymes as labels can 
allow improved sensitivity by providing a higher signal to noise ratio than 
radioisotopes. The other useful advantage is that using coated plates and enzyme 
labels provides a semi-automated assay which is simple to perform.
There is also the advantage that there is no radiation hazard involved, but since 
production o f the label involves the use o f  mutagenic chemicals and some o f the 
enzyme substrates are toxic, this is a marginal benefit.
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There are three main enzymes which are used as labels in immunoassays: alkaline 
phosphatase, p-D-galactosidase, and horseradish peroxidase (Ishikawaet. al. 1983). 
Assays employing alkaline phosphatase and conventional substrates do not give 
adequate detection limits for this particular application without extended incubations 
and will therefore not be considered further (Ishikawa et.al. 1983).
p-D-galactosidase was initially considered for use in this assay, since it is reported to 
provide a detection limit similar to and possibly lower than that of horseradish 
peroxidase, and there is a fluorimetric substrate available (4-methylumbelliferyl-p-D- 
galactoside) (Yoshitaki et. al. 1982) (Imagawa et. al. 1984). H owever P -D - 
galactosidase is a larger enzyme than peroxidase, (465 kD and 44 kD respectively) and 
it was thought that it may possibly cause steric hindrance problems in the assay. Since 
it had no major advantages over horseradish peroxidase it was considered to be ‘first 
reserve’ and peroxidase was the enzyme of choice.
1.5.6 The choice of substrate for horseradish peroxidase
Horseradish peroxidase has a number of colourimetric substrates: OPD (o-phenylene 
diamine), ABTS (2,2-azino-bis(3 ethyl thiazoline-6 -sulphonic acid)) and TMB 
(3,3',5,5'-tetramethyl-benzidine dihydrochloride) and also a fluorimetric substrate 
HPPA (3-(4-hydroxy phenyl) propionic acid). It was hoped that one or more of these 
substrates would provide the sensitivity required for the assay of growth hormone in 
urine. (Ishikawa et. al. 1983). It should be noted that the actual substrate of 
horseradish peroxidase in each case is H 2 O 2 and that the listed compounds are 
chromogenic indicators of H2O2 reduction (Bergmeyer 1986).
The H2O 2 can be added to the substrate solution immediately before the assay, or 
where the substrates are supplied in tablet form, it is generated on dissolution o f  the 
substrate.
ABTS is a safe substrate which produces a blue green colour in the presence of 
peroxidase which can be read at 405 nni, in timed and stopped assays, without a 
wavelength shift. The colour formation is due to a reversible redox system in which 
single electron transfers connect two different oxidation products (Figure 1.5.5), 
(Bergmeyer 1986) (Sigma Immuno Notes 1991).
There is a potential problem with TMB as a substrate in that oxidation in the presence 
of hydrogen peroxide produces two colour forms in sequence. A proposed reaction 
sequence is shown over (Figure 1.5.6), in which the blue primary product is in rapid 
equilibrium with the radical cation (Bergmeyer 1986). The use of 2 M H2 SO4 as a 
stop solution produces a yellow colour which can be read at 450 nrn. TMB is not as 
light sensitive as other substrates and can be developed in daylight, although there may 
be an effect on the blank values (Sigma Immuno Notes 1991).
HPPA is currently in limited use as a fluorimetric substrate of horseradish peroxidase 
and although it was previously measured using single cell fluorescence spectrometers, 
filters are now available for use with fluorescence platereaders. This allows assays 
using HPPA to be semi-automated. Unfortunately fluorescence plate readers are more 
costly than conventional colourimetric readers and are less commonly available within 
laboratories. In theory fluorescence substrates should provide a wider working 
range and greater sensitivity than their colourimetric equivalents.
1.5.7 Basic theory o f fluorescence
Some organic molecules are capable of absorbing radiation and emitting this energy in 
the form of photons of light which have longer wavelength and therefore less energy 
than the excitation radiation (Figure 1.5.7). The difference between the excitation 
wavelength and the emission wavelength is known as the Stokes shift. In general 
organic molecules have a Stokes shift of 30-50 nm, whereas the lanthanide chelates 
such as samarium or europium have Stokes shifts of over 200 nm. This means that
Figure 1.5.5
Oxidation products of  ABTS
Structure of ABTS showing the reversible formation of the two different 
oxidation products by single electron transfers. In the presence of 
peroxidase the blue green radical cation is formed which is stable if 
disproportionation is inhibited by a 100 fold molar excess of ABTS. 
(Bergmeyer et. al. 1986).
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Figure 1.5.6
Oxidation products of TMB
Oxidation of TMB, in the presence of peroxidase, produces two colour forms in 
sequence, the first being blue and the second brown. (Bergmeyer et. al. 1986)
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Figure 1.5.7
Principle of fluorescence
(adapted from Price and Newman 1991)
Inlcrsysicm crossing
Organic molecule or ligand Rare earth ion
the lanthanide chelates are less likely to present problems of distinguishing between 
excitation and emission wavelengths when selecting suitable filters to be used in the 
design of detection equipment. In addition when using pulsed excitation lanthanide 
chelates continue to fluoresce long after the interfering background fluorescence has 
decayed. These properties are used in time resolved fluorescence (Price and Newman 
1991).
Fluorescence enzyme immunoassays (FEIA) make use of enzymes which convert a 
non-fluorescent organic molecule into a fluorescent form and this fluorescent substrate 
is used simply as an alternative to colourimetric detection of enzymes. The advantages 
of fluorescent substrates tire wider measuring ranges and in theory greater sensitivity.
1.6 AIMS FOR THIS THESIS
The original primary aim for this thesis was to produce an assay to measure growth 
hormone in urine. It quickly became apparent however that there were intermediate 
aims, namely to investigate the production o f  antibody fragments and their use in 
producing enzyme conjugates; and to select the substrate capable of yielding optimal 
assay sensitivity.
The aims for the project were therefore:-
1) To produce an Fab' antibody fragment of anti-growth hormone IgG and to
conjugate this to either horseradish peroxidase or [3-D-gaIactosidase.
2) To produce an assay for urine growth hormone, using this conjugate as label,
and a colourimetric or fluorimetric substrate.
3) To measure urinary growth hormone in relevant groups of patient samples,
including children with short stature and acromegalic patients.
CHAPTER 2 : MATERIALS AND METHODS
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CHAPTER 2 MATERIALS AND METHODS
2.1 MATERIALS
ABTS [2,2-azino-bis (3 ethyl thiazoline-6-sulphonic acid)] 
Anti-human growth hormone monoclonal antibody G2 
Anti-human growth hormone monoclonal antibody G3 
Anti-human growth hormone sheep polyclonal IgG 
Avidchrome F(ab ')2 kit
Bovine albumin fraction V 
Casein
Centricon 30 microconcentrators 
DEAE cellulose DE 52
Enhanced luminescence substrate
Etched polystyrene beads
F(ab')2 Sheep IgG
Fab' sheep IgG
Horseradish peroxidase 
Horseradish peroxidase
HPPA (3-(p-Hydroxyphenyl)propionic acid)
Human growth hormone standard UK 9 (IRP 80/505)
4-(N-maleimidomethyl)cyclohexane-1 -carboxylic acid 
2-Mercaptoethylamine
Suppl ier
Sigma Chemical Co.
SAPU
SAPU
SAPU
Bio Probe 
International Inc.
ICN Biomedicals Ltd.
Presto
Amicon Corporation
Whatman 
Biochemicals Ltd.
Kodak diagnostics 
Ltd.
Northumbria
Biochemicals
Jackson Immuno 
Research
Jackson Immuno 
Research
Sigma Chemical Co.
Boehringer Mannheim 
GmbH
Aldrich Chemical Co. 
Ltd.
UK NEQAS, 
Edinburgh Royal 
Infirmary
Sigma Chemical Co. 
Sigma Chemical Co.
Microtitre plates 
Microti tre plates
Microtitre plates
N-Ethyl maleimide 
N-Hydroxy succinamide ester 
OPD (o-phenylene diamine)
Phosphate citrate buffer capsules 
Porcine pepsin
Porcine pepsin 
Rabbit IgG 
Sephadex G50 
Sheep IgG
TMB (3,3',5,5'-tetramethyl-benzidine dihydrochloride) 
Ultrogel ACA 44
Dynatech
Labsystems Flow 
Laboratories
NUNC
Sigma Chemical Co.
Sigma Chemical Co.
Sigma Chemical Co.
Sigma Chemical Co.
Boehringer Mannheim 
GmbH
Sigma Chemical Co. 
Sigma Chemical Co. 
Pharmacia 
Sigma Chemical Co. 
Sigma Chemical Co. 
IBF Biotechnics
All other reagents and chemicals were Analar grade from BDH (British Drug Houses)
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2.2 BUFFERS AND REAGENTS
2.2.1 Buffers
A) Sodium Phosphate Buffer 0.1 M, pH 8.0
A NaH2P0 4  2 H 2O M.W. 156.01 15.6 g dissolved in 1 litre deionised water
B Na2HPC>4 M.W. 141.96 14.2 g dissolved in 1 litre deionised water
Add B to A to adjust to required pH.
B) Sodium Phosphate Buffer 0.1M, pH 7.0 
A NaH2P 0 4 2HoO M.W. 156.01 15.6 g dissolved in
B Na2HP0 4  M.W. 141.96 14.2 g dissolved in
Add B to A to adjust to required pH.
C) Sodium Phosphate Buffer 0.1 M, pH 6.0 
A NaH2P 0 4 2H20  M.W. 156.01 15.6 g
B Na2HPC>4 M.W. 141.96 14.2 g dissolved in 1 litre deionised water
C Na2 EDTA 2H20  5 mM
M.W. 372.24 1.86 g
Dissolve A and C in 1 litre deionised water and add B to adjust pH to 6.0.
(filter before use)
D) Sodium Phosphate Buffer 17.5 mM pH 6.3
A NaH2P0 4  2 H 2O M.W. 156.01 2.73 g dissolved in 1 litre deionised
water
B Na2HPC>4 M.W. 141.96 2.484 g dissolved in 1 litre deionised
water
1 litre deionised water 
1 litre deionised water
Add B to A to adjust to required pH.
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E) Pepsin Digestion Buffer
Sodium Acetate Buffer 0.1M pH 4.5 
CH 3COO.Na (anhydrous) M.W. 82 8.2 g dissolved in 1 litre deionised water
Glacial acetic acid Add drop wise to adjust pH to 4.5
F) Tris HC1 Buffer 2.0 M, pH 8.0
T risH C IM .W . 157.6 17.76 g
Tris (hydroxy methyl) aminomethane hydrochloride
Tris base M.W. 121.1 10.6 g dissolved in 100 ml deionised
water
G) Tris HC1 Buffer 2.0 M, pH 8.0
Tris base M.W. 121.1 24.2 g dissolved in 100 ml deionised
water
HC1 10 % add drop wise to adjust pH to 8.0
H) OPD Peroxidase Substrate Assay Buffer 
Sodium acetate buffer 50 mM, pH 5.0 
Bovine albumin
I) Avidchrom Pepsin Digestion Buffer and 
Sodium acetate buffer 25 mM, pH 4.5
J) Avidchrom Hi Yield Binding Buffer
K) Avidchrom Hi Yield Elution Buffer
4.1g dissolved in 1 litre deionised water 
0.25 g
Dialysis Buffer 
Supplied with kit
Supplied with kit
Supplied with kit
L) Avidchrom Hi Yield Regeneration Buffer Supplied with kit
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M) Avidchrom Phosphate Buffered Saline pH 7.2
Sodium phosphate buffer 0.02 M 2ml 0.5 M PO4 to 50 ml
Sodium chloride 0.15 M M.W. 58.44 0.44 g
Sodium azide 0.01 % 0.005g
( azide is only added for long term storage of chromatography columns)
N) Conjugation Buffer
Sodium phosphate buffer 0.1 M, pH 6.5
A NaH2PC>4 2 H 2O M.W. 156.01 15.6 g dissolved in 1 litre deionised water
B Na2HP0 4  M.W. 141.96 14.2 g dissolved in 1 litre deionised water
Add B to A to adjust to required pH.
O) TMB and ABTS Peroxidase Substrate Assay Buffer
Phosphate citrate buffer pH 5.0 1 capsule in 100 ml deionised water
P)Peroxidase Fluorimetric Substrate Assay Buffer
Sodium phosphate buffer 10 mM, pH 7.0 Dilute 0.1 M Sodium Phosphate Buffer
B
Sodium chloride 0.1 M 0.58 g per 100 ml
Bovine albumin 0.5 g/litre 0.5 g per 100 ml
Q) Growth Hormone Plate Assay Buffer 
Sodium phosphate buffer 0.01 M, pH 7.0 
Sodium chloride 0.1 M 0.58 g per 100 ml
Bovine albumin 1 g/litre 0.1 g per 100 ml
Dilute 1 in 10 the 0.1 M buffer B which contains NaCl 1 M and add the BSA before 
use.
R) EPPS Buffer
EPPS 0.1 M, pH 8.0 M.W. 252.3 lO.lg in 500 ml 
(N-2 (2-Hydroxy ethyl)-piperazine-N-[3-propane-sulfonic acid]
NaOH Add approximately lg  to adjust pH to 8.0
S) Microtitre plate Coating Buffer 
K 2H P 0 4 2H20  0.05 M, pH 9.0
K 2HPO4 3H2O M.W. 228.23 Dissolve 11.4 g in 1 litre deionised water
2.2.2 Reagents
A) Peroxidase Fluorimetric Substrate
Tris buffer 0.1 M pH 7.8 20 ml
HPPA 7.5 g/litre 0.18 g or 1 tablet
(dissolving HPPA adjusts pH of Tris to 7.0)
H 2O2  4 ml
HPPA /Tris solution can be stored at 4° C for two months. The HPPA and H 2 O2 
should be allowed to reach room temperature and the H2 O2  is added immediately 
before use.
B) Saline /  Saline and Tween
Sodium chloride 9g dissolved in 1 litre deionised H2O
Tween 20 5 ml per litre
C) HPPA stop reagent
1.5 M glycine (amino acetic acid)
pH 10.3 M.W. 75.07 Dissolve 11.3 g in 100 ml deionised H2O
NaOH Add 2 M NaOH dropwise to adjust pH to
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2.3 PRODUCTION OF Fab’ FRAGMENTS
2.3.1 Purification of  IgG from polyclonal antiserum
IgG was precipitated from sheep polyclonal anti-growth hormone serum by the addition 
of Na2S0 4  followed by purification of the IgG by gel filtration using DEAE cellulose.
3.6 g of Na2 S0 4  was added slowly to 20 ml of neat sheep antiserum in a 50 ml 
conical Sarstedt tube. This was mixed for 30 minutes to ensure complete dissolution of 
the sodium sulphate. The mixture was spun at 2000 rpm for 10-15 minutes. The 
supernatant was discarded and the precipitate re-dissolved in 20 ml buffer A.
This purified IgG was then dialysed overnight against 600 ml of buffer A. The 
resulting dialysate was divided into 2 ml aliquots for further processing.
Mini columns of DEAE cellulose DE 52 were poured using 10 ml syringes with glass 
wool plugs and 3 way taps. The bed volume of each syringe was around 8 ml.
A 2 ml aliquot of IgG dialysate was added to a mini column and washed through with 
buffer A. Twenty 1 ml fractions were collected using a fraction collector. The 
absorbance at 280 nm was determined for each fraction and the peak fractions were 
pooled. The pooled fractions were then concentrated to by centrifugation at 4000 rpm 
in Amicon Centricon 30 microconcentrators until a final volume of 2ml was obtained. 
A fixed angle rotor was used to ensure that some liquid remained in the concentrators.
The amount of IgG present in the resulting concentrate was calculated using the 
extinction coefficient at 280 nm and the molecular weight of sheep Ig G .
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2.3.2 Pepsin  Digestion of IgG to F ( a b ')2
An aliquot of purified IgG (approx 5 mg/0.5ml) was dialysed overnight at 4 °C against 
200 ml of pepsin digestion buffer E.
0.2 mg of porcine pepsin was added per 5 mg of IgG. The pepsin solution was then 
incubated for 24 hours at 37 °C in an incubator (or water bath). The pH of the digest 
was adjusted to 7.0 using NaOH (or tris HC1 buffer F). The digest was centrifuged 
briefly to remove the precipitate which forms.
The digest was then added to an ACA 44 column (45cm x 1.5 cm) and eluted with 
buffer D. Ninety 2 ml fractions were collected and the peak fractions were identified 
by using a UV recorder (280 nm). The peak fractions containing F(ab')2 were pooled 
and concentrated to 0.45 ml using Amicon 30 microconcentrators. The amount of 
F(ab')2 produced was calculated using the extinction coefficient and molecular weight 
of F(ab ')2 •
In order to help interpret the resulting protein elution profile the column had previously 
been calibrated by running markers of bovine albumin, pepsin, sheep IgG, purified 
IgG, sheep F(ab')2> ar>d sheep Fab'.
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2.3.3 Avidchrome kit for F(ab')2 production
The kit is designed to digest 10 mg of purified IgG to produce F(ab ')2  .
A 10 mg/ml solution of partially purified IgG (SAPU sheep polyclonal anti-growth 
hormone) was prepared by adjusting the volume of a 25 mg/ml dialysed preparation 
with Avidchrom pepsin digestion buffer I. Solutions (10 mg/ml) of rabbit and sheep 
IgG (Sigma) were prepared by weighing out 10 mg of lyophilised IgG and adding 1.0 
ml of pepsin digestion buffer I.
One microcentrifuge tube of pepsin, as supplied in the kit, was dissolved in 100 ul of 
pepsin digestion buffer I. To this was added 1 ml of IgG followed by mixing and 
incubation for 6 hours or overnight at 37 °C in a water bath. The solution at this stage 
was turbid.
The sample was split into two 550 pi aliquots to each of which was added 600 pi of the 
Hi Yield binding buffer J, followed by mixing. 75 pi of anti-pepsin antibody was 
added to each microcentrifuge tube, which were vortex mixed and left to stand at room 
temperature for 15 minutes. The digest was then spun at 2000 g for 15 minutes to 
remove the turbid precipitate which forms. The clear supernatant was drawn up into a 
5 ml syringe with a needle.
Separation of the F(ab ')2 fragments was achieved using a protein A cartridge supplied 
with the kit. The protein A cartridge was regenerated, before use, by passing 5 ml o f  
Hi Yield regeneration buffer L through the cartridge at a flow rate of about 20 drops per 
minute (1 ml /m in) keeping the cartridge in a vertical position.
The cartridge was equilibrated with 4 ml of Hi Yield binding buffer J at a flow rate of 
about 20 drops per minute.
The IgG digest was passed through the column at 10 drops per minute (0.5 ml /  min). 
The effluent was collected into a 15 ml Henley tube. The cartridge was rinsed with 1 
ml of Hi Yield binding buffer J, using the same syringe and this effluent was collected 
into the Henley tube.
The combined 3.45 ml of flow through fraction, containing the F(ab ')2  fragments, was 
dialysed using 10 cm of 50,000 MW cut-off dialysis tubing against phosphate buffered 
saline M to remove the smaller peptides. The F(ab')2 fragments were then concentrated 
to 1 ml using Amicon 30 miniconcentrators.
The cartridge was rinsed with 5 ml of Hi Yield binding buffer J and the effluent 
discarded. The Fc fragments and undigested IgG were eluted from the cartridge with 5 
ml Hi Yield elution buffer K. The cartridge was washed with 10 ml of phosphate 
buffered saline M containing 0.01 % sodium azide and stored at 4 °C.
2.3.4 Reduction of F(ab')2 1° Fab'
The F(ab')2 fragment of sheep IgG (2-5mg /  0.45ml) was prepared using either the 
Avidchrom kit (Section 3.3), or the method of Ishikawa et. al. (1988) (Section 3.2), in 
a Sarstedt microcentrifuge tube. 50 ul of 2-mercaptoethylamine (0.1 M) in sodium 
phosphate buffer D was added and incubated for 1.5 hours at 37 °C in a water bath.
The reaction mixture was then added to a column (1.5 x 90 cm) of Ultrogel ACA 44 at 
a flow rate of 20 ml per hour using buffer D which contains EDTA to prevent re­
association of the Fab' fragments. The method of Ishikawa et. al. (1988) shows the 
use of a 45 cm column of ACA 44 but this did not give adequate separation and a 90 cm 
was used. Ninety 6 minute fractions (2 ml) were collected and a 280nm UV detector 
used to monitor the peak fractions from the column. This confirmed the complete split
of the F(ab '>2 fragment to Fab' fragments. The peak fractions were pooled and 
concentrated using Amicon Centricon-30 concentrators.
The amount of Fab' produced was calculated from the extinction coefficient at 280 nm 
and the molecular weight.
2.4 PRODUCTION OF PEROXIDASE Fab' CO N JUG ATE
2.4.1 Introduction of  maleimide groups into horseradish peroxidase
Buffer D (0.3 ml) was added to 2 mg of horseradish peroxidase in a Sarstedt micro 
centrifuge tube, and vortex mixed. Maleimide (0.7 mg) (n-succinimidyl-4-(n- 
maleimidomethyl) cyclohexane-l-carboxylate was weighed into another micro­
centrifuge tube and dissolved in 0.03 ml of n,n dimethyl formamide. This process was 
performed in a fume cupboard. The maleimide-formamide mixture was warmed to 30 
°C in a water bath to prevent precipitation of the peroxidase. The maleimide was then 
transferred into the peroxidase tube. The mixture was incubated at 30 °C in a water 
bath for 1 hour. The maleimide could be replaced with n-succinimidyl-6- 
maleimidohexanoate which is more soluble in the reaction mixture and does not require 
the toxic solvent dimethyl formamide (Flashida et. al. 1984).
The mixture was centrifuged briefly to remove the white precipitate which formed and 
the brown supernatant was added to a 5 ml Sephadex G 50 fine mini column, made up 
in a 10 ml syringe with a glass wool plug.
Twelve 1 ml fractions were collected and the absorbance at 280 and 403 nm of each 
was measured. The peroxidase activity in each fraction was measured using OPD as 
substrate.
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2.4.2 Peroxidase assay of column Tractions
In order to identify which column fragments showed peroxidase activity, a quick 
screening assay protocol was developed using OPD as substrate.
The column fractions were initially screened using 10 pi of column fraction and 200 
pi of buffer. The dilution was then increased for the peak fractions which gave 
absorbance values above 3.0. The assay was set up in microtitre wells and read using a 
plate reader. The high levels of enzyme present mean that the assay should be read 
within five minutes of adding the hydrogen peroxide.
The assay protocol was as follows. To 2 p.1 diluted column fractions was added 200 
pi OPD (one 10 mg tablet dissolved in 25 ml buffer H). The enzyme reaction was 
started by addition with a repeating pipette of 10 pi of H2O 2 (1/6 dilution of 30 % 
s tock). The assay was mixed on a plate mixer briefly and read immediately 
(unstopped) at 450 nm on a plate reader.
2.4.3 Conjugation of  Fab' fragment to maleimide peroxidase
Maleimide-peroxidase (1.8 mg, 45 nmol) was incubated with Fab' fragment (2.0 mg 
43 nmol) in 1 ml of sodium phosphate buffer G at 4 °C for 20 hours or at 30 °C for one 
hour. The final concentrations of the maleimide peroxidase and Fab' fragment should 
be 0.01-0.05 mM.
The mixture was then added to a 90 cm column of ACA 44 at a flow rate of 20 ml/hr 
using conjugation buffer N. Ninety 6 minute fractions of 2 ml were collected.
The absorbance of each fraction at 280 and 403 nm was determined, and the peroxidase 
activity measured as described in section 2.4.2. The binding of the Fab'-peroxidase 
was tested for the two pooled peak fractions and the intercept fraction as in section 
2 4 .5 .  The F ab ’-peroxidase was concentrated by a factor of 10 using Amicon 
Centricon 30 concentrators and stored at 4 °C. Thiomersal (2-5 g/1) was added at 1/98 
volume as a preservative. Sodium azide is unsuitable as a preservative as it inactivates 
peroxidase. Bovine albumin (100 g/1) was added at 1/98 volume as required.
2.4.4 C oa ting  o f  m ic ro t i t r e  p la te  wells
Anti-growth hormone G2 monoclonal antibody (5 p g /  200 p.1) diluted in plate coating 
buffer S was added to microtitre wells and the plate was incubated overnight at room 
temperature covered with adhesive tape. The G2 was recovered for re-use and the 
wells were washed 3 times in saline reagent B. Bovine albumin ( 300 |il of 0.5 % 
BSA) diluted in plate coating buffer S was then added to overcoat the wells followed by 
overnight incubation at room temperature. The plate was washed 3 times in saline 
regent B prior to assay.
2.4.5 Assay to test b ind ing  of label f rac tions
Growth hormone standard (UK 9) was diluted in growth hormone plate assay buffer Q 
to give standards of: 0, 0.1, 1.0, 10.0 mU/1. Standards (200 p.1) were added to wells 
coated with G2 (methods section 2.4.4) and the plate incubated overnight at 4 °C 
covered with adhesive tape.
The wells were washed three times in saline and blotted dry. Fab'-peroxidase peak 
fractions (Section 2.4.3) were diluted 1 in 50 in assay buffer and 200 ul was added to 
each of the wells. The plates were again incubated washed and blotted dry.
Immediately before use one OPD substrate tablet was dissolved in 50 ml buffer H  and 
200 pi was added to the wells. H2O2 (10 |al of 1/6 dilution of 30 % stock) was added 
to stan the reaction. The plate was incubated on a plate shaker for 30 minutes wrapped 
in a paper towel to exclude light. The colour developed in each well was determined at 
450 nm using a plate reader. The standard curves were plotted for the two peaks and 
the intercept region of the Fab'-peroxidase purification.
2.5 GROWTH HORMONE ELISA
2.5.1 Coating microtitre wells
Partially purified G2 or G 3 monoclonal anti-growth hormone antibody was diluted in 
plate coating buffer S to a concentration of 5 jag per 200 pi. This antibody was added 
to microtitre wells (200 pi per well). The plates were covered with clear adhesive tape 
and left at room temperature from Friday to Monday morning (approximately 65 
hours).
The antibody was recovered for re-use and the plates were washed 6 times in saline 
reagent B using a plate washer. The plates were left for a few minutes inverted on 
paper towels to drain off the remaining wash solution. Overcoating material (300 pi of 
BSA or casein) was then added at a concentration of 0.05%, diluted in plate coating 
buffer S. The plates were covered and incubated overnight at room temperature.
The plates were washed 6 times in saline and Tween reagent B inverted and left to drain 
for a few minutes. The plates were then ready for immediate use or for storage at 4 °C 
in a sealed polythene bag containing moist filter paper.
2.5.2 ELISA using OPD substrate
G2 or G3 coated plates (5|ig /  200pl) were prepared as detailed in the methods section
2.5 .1 .
Human growth hormone standard (UK 9) was diluted in growth hormone plate assay 
buffer Q to give concentrations of: 0.0, 0.001 , 0.01, 0.1, 1.0, 10.0 mU/1. Standard, 
buffer, or sample (200 |il) was added to wells in duplicate using the plate layout shown 
in Figure 2.5.1 and the plate was incubated overnight at 4 °C covered with adhesive 
tape.
The plate was washed 6 times in saline and Tween reagent B using an automatic plate 
washer and blotted dry on paper towels. Fab' peroxidase label was diluted 1/500 in 
Assay Buffer Q and 200 |il was added to each well. The plate was covered and 
incubated overnight at 4 CC.
The plate was washed 6 times and blotted dry.
Immediately before use one 10 mg tablet of OPD was dissolved in 50 ml of growth 
hormone plate assay buffer Q. H 2O2 (30% stock) was diluted 1/6 in distilled H 2O.
OPD substrate was added with a repeating pipette (200 p.1 per well) followed by H 2O2 
(10 pil) to start the reaction. The plate was then covered with a paper towel to exclude 
light and incubated on a plate mixer at room temperature for up to 2 hours. The optical 
density of the wells was measured at 450 nm on a plate reader.
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Figure 2.5.1
Layout of growth hormone standard replicates on a microtitre strip.
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4, 10 - 0.1
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2.5.3 ELISA using ABTS substrate
G2 or G3 coated plates (5pg /  200pl) were prepared as detailed in the methods section
2 .5 .1 .
Human growth hormone standard (UK 9) was diluted in growth hormone plate assay 
buffer Q to give concentrations of: 0.0, 0.001 , 0.01, 0.1, 1.0, 10.0 mU/1. Standard, 
buffer, or sample (200 pi) was added to wells in duplicate using the plate layout in 
Figure 2.5.1, and the plate was incubated overnight at 4 °C covered with adhesive 
tape.
The plate was washed 6 times in saline and Tween reagent B using an automatic plate 
washer and blotted dry on paper towels.
Fab' peroxidase label (200 pi) diluted 1/500 in Assay Buffer Q was added to each well. 
The plate was covered and incubated overnight at 4 °C.
The plate was washed 6 times and blotted dry as above.
Immediately before use a 10 mg tablet of ABTS was dissolved in 100 ml of ABTS 
substrate assay buffer O.
ABTS substrate was added to each well with a repeating pipette (200 pi per well). The 
plate was then incubated on a plate mixer at room temperature for up to 2.5 hours 
wrapped in a paper towel to exclude light. The optical density of the wells was 
measured at 405 nm on a plate reader.
2.5.4 ELISA using TMB substrate
G2 or G3 coated plates (5pg / 200pl) were prepared as detailed in the methods section
2 .5 .1 .
Human growth hormone standard (UK 9) was diluted in growth hormone plate assay 
buffer Q to give concentrations of: 0.0, 0.001 , 0.01, 0.1, 1.0, 10.0 mU/1. Standard, 
buffer, or sample (200 pi) was added to wells in duplicate using the plate layout in 
Figure 2.5.1 and the plate was incubated overnight at 4 °C covered with adhesive tape.
The plate was washed 6 times in saline and Tween reagent B using an automatic plate 
washer and blotted dry on paper towels.
Fab' peroxidase label (200 pi) diluted 1/500 in Assay Buffer Q was added to each well. 
The plate was covered and incubated overnight at 4 °C.
The plate was washed 6 times and blotted dry.
Immediately before use a 1 mg TMB substrate tablet was dissolved in 10 ml TMB 
substrate assay buffer O in a Henley tube. The Henley tube was spun briefly to remove 
the small amount of undissolved substrate and the substrate was transferred to a clean 
container. As TMB is toxic the substrate tablets were not handled and inhalation of 
dust from the tablets was avoided.
TMB substrate (200 pi) was added to each well with a repeating pipette. The plate was 
covered with a paper towel, to exclude light, and incubated for 30 minutes on a plate 
shaker at room temperature.
Stop reagent (50 pi H 2SO4 , 2 M) was added to each well, causing a colour change 
from blue to yellow. The plates were read immediately at 450 nm on the plate reader. 
Where the absorbance of the well exceeded 3.0 absorbance units the well contents were 
diluted x 2 in TMB substrate assay buffer O and the measurement repeated.
2.5.5 T M B  t r a n s f e r  assay
Fab’ Peroxidase label (200 pi) was added to 200 pi urine, dialysed urine and buffer 
standards in a blank microtitre plate and incubated overnight at 4 °C. From each well 
200 pi was then transferred to G2 coated plates (5pg/200pl) prepared as detailed in the 
methods section 2.5.1. The plate was then incubated overnight at 4 °C covered with 
adhesive tape. The plate was then washed with saline, 200 pi of TMB added followed 
by incubation and measurement of the optical density as in section 2.5.4.
2.5.6 F luo rescence  enzym e im m u n o assay  (FEIA ) using  H P P A  s u b s t r a te
G2 or G3 coated plates (5pg / 200pl) were prepared as detailed in the methods section 
2.5.1.
Human growth hormone standard (UK 9) was diluted in growth hormone plate assay 
buffer Q to give concentrations of: 0.0, 0.001 , 0.01, 0.1, 1.0, 10.0 mU/1. Standard, 
buffer, or urine (2 0 0  pi) was added to wells in duplicate and the plate incubated 
overnight at 4 cC covered with adhesive tape.
The plate was washed 6 times in saline and Tween reagent B using an automatic plate 
washer and blotted dry on paper towels.
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Fab' peroxidase label (200 pi) diluted 1/1000 in Assay Buffer Q was added to each 
well. The plate was covered and incubated overnight at 4 CC.
The plate was washed 6 times and blotted dry as above.
HPPA was dissolved in 0.05 M Tris buffer pH 7.8 (7.5g per litre). Immediately 
before use five volumes of HPPA were mixed with one volume of 0.06% H 2 O2 . The 
HPPA solution and H 2O 2 were allowed to come to room temperature in the dark before 
use.
HPPA substrate (200 pi) was added to each well with a repeating pipette. The plate 
was incubated for 60 minutes on a plate mixer at room temperature. Stop reagent ( 100 
pi of 1.5 M glycine buffer pH 10.3) was added to each well. The fluorescence was 
read on a Fluoroscan II plate reader, the excitation and emission wavelengths being 320 
and 405 nm respectively.
2.5.6.1 Recrystalisation of HPPA fluorimetric substrate
The following protocol was followed unsuccessfully in an attempt to purify the HPPA 
substrate supplied by Sigma. The HPPA used in the fluorescence assay (methods 
section 2.5.6) was supplied by Labsystems Finland and had been purified by Helsinki 
University Department of Chemistry.
The HPPA available commercially was recrystalised before use to provide the best 
possible purity.
2g of HPPA was added to 50 ml of distilled water and heated to 50-60 °C on a hot plate 
with a magnetic stirrer until the substrate dissolved. The minimum amount of distilled 
water was used to dissolve the substrate.
The substrate was removed from the hot plate and allowed to cool to room temperature. 
It was then cooled further in the fridge to 4 °C to allow the crystals to form. The 
substrate was allowed to cool slowly to maximise the purity of the crystals at the 
expense of a high yield of substrate.
The crystals were recovered by filtering under vacuum through a Whatman filtration 
system with microfibre glass filter pads. The crystals were rinsed with ice cold distilled 
water.
The crystals were allowed to dry on filter paper and then transferred to a desiccator. 
Once dry the crystals were weighed and the recovery calculated.
2.5.7 E n h a n c e d  L u m inescence  assay
Human growth hormone standard (UK 9) was diluted in growth hormone plate assay 
buffer Q to give concentrations of: 0.0, 0.001 , 0.01, 0.1, 1.0, 10.0 mU/1. Standard 
(200 p.1) was added in duplicate to wells of NUNC G2 coated plates (5 |ig /  200 |il) 
prepared as in section 2.5.1. The plates were incubated and washed as in the methods 
section 2.5.6. Kodak Amerlite enhanced luminescence signal reagent was prepared by 
adding one tablet A and one tablet B to a bottle of signal reagent buffer. Immediately 
after the plate was washed the signal reagent was added (250 j l x I  per well) and the plate 
was read in the luminescence plate reader five minutes later (2-20 minutes).
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2.6 U R IN E  ASSAY
2.6.1 Dialysis  of  urine
Fresh urine was collected and a measured volume was dialysed overnight at 4 °C using 
dialysis tubing with a 12 to 14 000 molecular weight cut off and 600 ml of growth 
hormone plate assay buffer Q which contains 1 g/1 BSA. The volume of the urine after 
dialysis was checked to ensure that there was no significant loss of urine during the 
dialysis procedure.
2.6.2 Spiked urines
Growth hormone standard UK 9 was diluted in growth hormone plate assay buffer Q 
and added to measured volumes of urine and dialysed urine.
CHAPTER 3 : EVALUATION OF REAGENTS AND RESULTS
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CHAPTER 3 : EVALUATION OF REAGENTS AND RESULTS
3.1 PR ODUCTION OF ENZYME CONJUGATE
3.1.1 Purification of  sheep anti growth hormone antiserum
Growth hormone antiserum was purified as detailed in the methods section 2.3.1. The 
peak produced was monitored by measuring the A 280 nm of each fraction. A typical 
column chromatography profile is shown (Figure 3.1.1). The IgG produced was 
concentrated and the amount of protein present was estimated from the A 280 nm 
according to the formula .
A = £CL
Where A is the absorbance of a pure protein at 280 nm, C is the concentration of the 
protein in moles per litre, L is the path length of the cuvette, usually 1 cm, and £  is the
molar extinction coefficient for the protein
Hence C = A/£
The extinction coefficient for sheep IgG is 1.5 H c n r 1 and the molecular weight is 150 
KD. The stock IgG for use in fragment production was calculated to contain 23.7 g/1.
3.1.2 Pepsin digestion of IgG to F(ab')2
Initially albumin was used as a molecular weight marker to characterise the fragments 
obtained from the column purifications of IgG digestion. Unpurified sheep antiserum, 
purified sheep antiserum and sheep F(ab')2 were then all run on the column to indicate 
in which fractions they eluted (Figure 3.1.2). Pepsin was also run to check that it did 
not co-elute with any other major fragment. Pepsin was shown to be a minor peak 
which elutes before IgG and was therefore not considered further. The sheep IgG 
profile had two peaks the second of which was considered to be IgG and the first was 
thought to be polymers of IgG.
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3.1.3 R ed u c t io n  of F (ab ')2  to F ab '
Many attempts were made to produce Fab' from F(ab')2, as detailed in the Methods 
Section Chapter 2.3.4. It was not possible to determine whether Fab' had in fact been 
produced since run to run variations in the elution fractions suggested that the 45 cm 
column was not capable of resolving Fab1 from F(ab')2- Markers o f  sheep Fab' and 
F(ab')2 were used individually and mixed together in equal proportions to determine if 
they could be resolved by the column and these showed that there was considerable 
overlap of the peaks using this column length (Figure 3.1.3). A 100 cm column was 
then prepared and when the mixture of markers was run, adequate separation was 
achieved (Figure 3.1.4). This longer column was adopted for all further experiments.
Use of the longer column showed that the F(ab')2 produced was not being reduced to 
Fab' successfully. An alternative kit method of producing F(ab')2 was examined using 
Sigma Sheep IgG and sigma rabbit IgG as sources of IgG to preserve the stocks of 
anti-growth hormone antiserum. F(ab')2 was successfully produced from both of these 
and subsequently Fab' was obtained from them using mercapto-ethylamine reduction as 
detailed in the methods section 2.3.4. (Figure 3.1.5), (Figure 3.1.6), (Figure 3.1.7). 
The kit was used to produce F(ab')2 from the SAPU anti HGH antiserum and from this 
Fab' was obtained using the method detailed in Chapter 2.3.4.
There are several possible theories to explain why the F(ab')2 could not be reduced to 
Fab' using the original method of Hashida et. al. (1985). Firstly, the material produced 
may have been altered or damaged such that it could not be further reduced. This is 
unlikely since the methods of production were very similar, although different 
concentrations or acidity of the buffers may have led to conformational changes in the 
F(ab')2- Secondly, one of the steps may not have been optimized sufficiently for sheep 
IgG and, for example, the pepsin digestion may have been incomplete or excessive. 
Thirdly, the Fab' produced was being immediately reconverted to F(ab')2- This is
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unlikely as the F(ab')2 produced using the Pearce kit was successfully reduced to Fab' 
using the same method. Attempts were made to investigate this problem, including the 
use of thiol blocking to prevent the reformation of F(ab')2 from Fab', but the results 
were inconclusive and due to time limitations the Pearce method was adopted as it was 
much more simple and quicker to carry out.
An attempt was made to monitor the pepsin digestion of IgG by removing 20 ml of 
digest and adding 17 ml of NaOH to adjust the pH to 7.0 hence stopping the digestion. 
This was repeated at a series of steps from one hour to 24 hours and the products were 
run on a protein electrophoresis gel. The IgG band on these strips gradually 
disappeared over the 24 hour time course forming a transient digestion product band 
which appeared at around one hour of digestion and disappeared after four hours, the 
production of F(ab')2 could not be shown but a diffuse pre-origin band increased in 
intensity during the incubation period. Markers of Fab' and F(ab')2 were also 
examined using electrophoresis and the sheep markers formed a similar pre-origin band 
while the rabbit markers formed an immediately post-origin band. Since the Fab' could 
not be distinguished from the F(ab')2 the technique was considered of little use and 
was abandoned. The alternative of Poly Acrylamide Gel Electrophoresis (PAGE) could 
not be undertaken within the constraints of the project.
3.1.4 Thiol b locking of Fab'
The thiol groups of Fab' were blocked with N-ethyl maleimide to check whether the 
Fab' was re-forming F(ab')2. There appeared to be some re-formation of F(ab')2 and
it was suggested that if the Fab' was not to be used immediately then it should be thiol
blocked (Figure 3.1.8). The Fab' prepared for conjugation was used immediately after
preparation. It is not clear from the publications of Ishikawa whether or not thiol 
blocking affects the conjugate formation.
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Figure 3.1.8
Profiles of Sigma sheep Fab' and thiol blocked Fab1 
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3.1.5 Production of horseradish peroxidase maleimide
The purification o f horseradish peroxidase-maleimide produced two peaks when the A 
403 nm was measured for each fraction, but only one peak at A 280 nm (Figure 3.1.9). 
The majority o f the horseradish peroxidase activity was to be found in the first peak 
(Figure 3.1.10) and several experiments were devised to identify the second peak. 
These experiments included applying the various components individually and in 
combination to columns and collecting fractions. The components included: horseradish 
peroxidase (Figure 3.1.11), maleimide (Figure 3.1.12), horseradish peroxidase in 
formamide (Figure 3.1.13), and horseradish peroxidase which had been incubated at 
30 °C for one hour to replicate the horseradish peroxidase maleimide conjugation 
procedure (Figure 3.1.14). The maleimide on its own gave a small peak in the region 
of the second peak but its peak height was much lower than in the horseradish 
peroxidase-maleimide purification. This second peak appeared to be a reaction product 
which had little or no horseradish peroxidase activity. The peak was not the result of 
damage to horseradish peroxidase by formamide or due to formamide itself.
The relative quantities o f maleimide and horseradish peroxidase were adjusted to 
optimize the linking and the effect o f extending the incubation time from one to two 
hours was examined (Figure 3.1.15) and it was shown that there was no significant 
advantage in increasing the amount of maleimide or in extending the incubation time to 
two hours.
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3.1.6 Conjugation of Fab' with horseradish peroxidase-maleimide
The product of the horseradish peroxidase-maleimide conjugation was characterised by 
purification on an AC A 44 column (100 cm) with each o f the fractions produced being 
examined for their absorbance at 280 and 450 nm and for their horseradish peroxidase 
activity (Figure 3.1.16). These all showed two large peaks with a cross-over area. 
Since the first peak was of larger molecular weight, having the shortest retention time, 
it was anticipated that this would prove to be the conjugate.
3.1.7 Test of binding of label fractions
The two peaks obtained from the purification o f the product from the Fab' peroxidase- 
maleimide conjugation were examined for growth hormone binding by setting up a 
simple ELISA using plates coated with G2 anti growth hormone antiserum and OPD 
substrate. Fractions around both peaks were tested and in addition a fraction at the 
cross-over point o f the two peaks was tested. Peak one showed most binding, the 
cross-over showed less binding, and peak two showed no significant binding (Figure 
3.1.17). It was concluded that peak one contained the conjugate o f peroxidase and 
Fab', peak two may consist o f unconjugated Fab' and unconjugated horseradish 
peroxidase and the cross-over contained a mixture of both. Since the second peak had 
considerable peroxidase activity it was considered to be mainly unconjugated 
horseradish peroxidase. The Fab' should be present in excess to prevent linkage of 
Fab' with more than one peroxidase molecule but it would appear from the amount o f  
peroxidase activity remaining in the second peak that in this case the horseradish 
peroxidase was in slight excess.
The recovery o f fragments at each stage o f the conjugate production was low and the 
overall recovery o f Fab'in the label was calculated as 36%. However since only small
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amounts of label were required this was not of immediate concern, although further 
investigations would be advisable if the method were to be used frequently.
3.2 DEVELOPMENT OF A PRELIMINARY ASSAY ON PLATES
Initially an assay was set up using OPD as a substrate but since the colour changes 
produced were so minimal the conjugate production was almost considered a failure 
until alternative substrates were examined. These substrates showed much better colour 
development than OPD making it possible to proceed with the assay development.
Using the preliminary OPD assay the concentration o f antibody coated to the plates, the 
label dilution, incubation times and temperatures were all optimised. These 
experiments provided general guide-lines which were later re-checked as the TMB 
assay was improved.
3.2.1 Colourimetric substrates: ABTS,TMB,OPD
A variety of different substrates and incubation times were investigated to determine 
which gave the highest signal to noise ratio. ABTS and TMB proved to be useful 
substrates while OPD gave a very small change in colour and was not used further 
(Figure 3.2.1). TMB and ABTS can be read either unstopped after a set time or more 
conveniently by addition o f a strongly acidic or alkaline solution which stops the 
enzyme reaction. In the case o f TMB a colour change from blue to yellow results 
providing a larger change from the blank value and improved sensitivity. Optimizations 
of the incubation times for ABTS and TMB using G2 and G3 plates are shown (Figure 
3.2.2), (Figure 3.2.3), (Figure 3.2.4). TMB was found to be the better substrate and 
was selected for use in later experiments.
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3.2.2 Coating of microtitre plates
Different coating concentrations were investigated and two different monoclonal 
antibodies were used for coating known as HGH G2 and G3. The optimal coating 
concentration for G2, judged as the signal to noise ratio (A/A 0 standard) was between
2.5 and 5 mg per 200 ml (Figure 3.2.5 a). The optimal coating concentration for G3 
was similar to that o f G2 although the plateau was not so evident (Figure 3.2.6 a). 
Similar standard curves were obtained using G2 (Figure 3.2.5 b) and G3 (Figure 3.2.6 
b) and there was little to choose between the two antibodies. Due to the availability of 
antisera antibody G2 was used for the the majority o f further experiments although 
antibody G3 was not rejected.
Different coating temperatures were also studied showing, as expected, that room 
temperature provided better binding than 4 °C (Figure 3.2.7). Investigation o f the time 
of coating showed that extending the coating time improved the binding (Figure 3.2.7).
In order to provide a protocol which could include coating, over-coating and an assay 
in one week while minimising plate storage time, the plates were coated on Friday, 
over-coated on Monday, the assays were set up on Tuesday and completed on 
Thursday.
3.2.3 Label concentration
A range o f peroxidase-Fab' label dilutions was evaluated to show which gave the best 
signal to noise ratio (A / A 0 standard) across the standard curve while using as little 
label as possible. The optimal dilutions were 1 in 500 and 1 in 1000 o f the stock label 
(Figure 3.2.8). In the preliminary assays 1 in 500 had been used but subsequent to this 
optimization 1 in 1000 was used to conserve the label as both dilutions were found to 
perform adequately.
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3.2.4 Over-coating of microtitre plates
The concentration o f BSA used for over-coating or blocking the antibody coated plates 
was optim ised over a range from 0.05 % to 1 %, 0.5 % being commonly 
recommended. For this application the optimal concentration was found to be 0.05 % 
for G2 plates (Figure 3.2.9) and 0.5 % for G3 plates (Figure 3.2.10). Increasing the 
concentration o f BSA appeared to increase the blank values in both G2 and G3 coated 
plates. The optimum over-coating concentration o f BSA differed when using G2 and 
G3 coated plates and decreasing the BSA concentration appeared to increase the signal 
and the signal to noise ratio in G2 plates but it had the reverse effect in G3 plates.
Casein from dried milk powder was examined as an alternative over-coating material to 
BSA and this was found to be marginally better than BSA and was adopted for further 
use at 0.05% (Figure 3.2.11) (Livesey and Donald 1982). There may be useful 
information to be gained from investigating the use of alternative over-coating reagents 
such as F(ab')2 as recommended by Hashida et. al. (1985).
3.2.5 Assay buffers
Epps buffer pH 8 was examined as an alternative to phosphate buffer pH 7. 
Surprisingly Epps buffer was found to perform badly in this application despite the fact 
that it is used routinely in the IRMA and DELFIA growth hormone assays used in this 
Department (Figure 3.2.12).
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3.2.6 Precision study and derivation of theoretical sensitivity
Ten sets of standards were assayed in parallel to examine the theoretical sensitivity for 
the TMB colourimetric assay Figure (3.2.13 a). Theoretical sensitivity for the 
colourimetric assay was 0.004 mU/1 and was calculated as follows.
St = 2 SDAo x Cst /  (Ast - Ao), where 
St - theoretical sensitivity
SDAo - standard deviation o f the fluorescence o f the zero standard
Ast - mean absorbance of the lowest standard giving coefficient o f variation o f less
than 10 %
Ao - mean absorbance of the zero standard 
Cst - concentration of the standard giving A st
Due to time limitations less data was available for the luminometric assay but a mean 
standard curve o f 4 sets o f luminometric standards is shown (Figure 3.2.13 b) a 
sensitivity of 0.001 mU/1 is not unrealistic. The fluorimetric assay (Figure 3.2.13 c) 
suffers from reagent blank problems and the sensitivity is around 0.1 m U/1.
3.2.7 Optimisation of the washing step
The number o f washes used between the steps o f the reagent additions was increased 
from three to six to test whether the blank value was dependant on washing. The use 
of Tween as an additive to the saline wash was investigated as generally Tween is 
considered to provide more efficient washing but for this application this was not found 
to be the case (Figure 3.2.14). Six washes were used between reagent additions as it 
was considered that this should be more than adequate. Tween was not used between 
coating and over-coating since it was considered that this may reduce the binding of the
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BSA or casein to the plate. Azide was not used as a preservative in any o f the buffers 
or wash solutions as it inhibits peroxidase activity.
Considerable care was required to ensure that the plates were completely dry between 
washing and reagent additions as the plate washers did not leave the plates dry. The 
plates were 'bashed' dry on paper towels and allowed to stand, inverted, for a few  
minutes after washing.
3.2.8 Sensitivity o f TM B to light
The substrate reaction for TMB was carried out in daylight and with light excluded by 
covering the plate with a paper towel to investigate whether the blank values increased 
due to any light sensitive reaction o f the substrate (Figure 3.2.15). The substrate 
reaction was carried out in the dark thereafter since it was felt that there was a slight 
increase in blank readings when the plates were incubated in daylight. The TMB 
substrate was made up immediately before addition as it changes colour from clear to 
blue when exposed to light for short periods of time.
3.2.9 D ifferent m anufactures o f m icrotitre plate
A variety of different manufacturers microtitre plates were used to examine for any 
differences in binding and reproducibility of coating (Figure 3.2.16). NUNC plates 
were used for the majority o f the experiments of the project and none o f the other types 
tried were found to be significantly better. It was felt that reproducibility o f coating of 
the plates was a major problem leading to imprecision in the assay and unexplained 
outliers. It was also felt that increasing the binding of the growth hormone antibody to 
the plates may improve the signal obtained but this appeared not to be the case. 
Covalent linking o f the antibody to the plates was not attempted and this may improve 
the binding.
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A high binding plate from Labsystems was assessed to determine if  there was any 
enhancement of binding or improvement o f coating precision but this was not found to 
be the case (Figure 3.2.17).
3 .2 .10  E dge effects
In a number o f assays the blank value for the zero standard gave higher readings than 
the lowest standard and this was thought to be possibly due to edge effects on the 
plates. In order to investigate this phenomenon, a complete plate o f blanks was set up 
and mean absorbances were calculated for each row and each column to identify if there 
were differences across the plate and up and down the plate. There appeared on 
occasion to be a slight effect across the plate but this was not reproducible (Figure 
3.2.18).
3.2.11 F luorescence assay using H PPA substrate
HPPA was used as a fluorescence substrate to investigate if there was a potential gain 
in sensitivity or in measuring range over TMB.
Peroxidase label was diluted over a range of concentrations to assess the range o f the 
fluorescence plate reader (Figure 3.2.19).
Dialysed and undialysed urine from a normal adult was spiked at a number o f levels 
with growth hormone and assayed to investigate the presence of a urine matrix effect 
(Section 3.3.3). Two different types of plates were used to ensure that there were no 
significant variations in coating between different types o f plate (Section 3.3.3).
From these experiments it was concluded that HPPA had a much wider working range 
than TMB, as shown by Tuuminen et. al. (1991), but that the poor background
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readings obtained from the substrate limit the potential sensitivity obtainable. This 
background problem is due to impurities in the commercially available substrate, which 
are not easily removed. It may be that plate readers in general whether they are 
colourimetric or fluorimetric are not as sensitive as the best fluorescence spectrometers, 
and this may be the price to pay for automation against using labour intensive single cell 
detectors.
3.2.12 Enhanced luminescence assay
The assay was adapted to use an alternative enhanced luminescence peroxidase 
substrate which consists of a luminol derivative, a peracid salt and a substituted phenol 
enhancer. The enhancer increases the amount o f light produced and prolongs its 
emission. (Whitehead et. al. 1983) The standard curve obtained is shown (Figure 
3.2.20 ) and from this initial trial run this substrate appears to provide a better signal to 
noise ratio and a lower detection limit than that o f HPPA or TMB and within the range 
necessary for a viable urine growth hormone assay. Unfortunately the equipment was 
not available for an extensive evaluation of the assay.
3.3 APPLICATION OF THE ASSAY TO URINE SPECIMENS
3.3.1 Linearity of the growth hormone assay in the presence of urine
A urine sample from a normal adult was serially diluted in assay buffer (neat x2 x4 x8 
). These diluted urine samples were spiked with growth hormone standard and then 
subsequently diluted in assay buffer to provide a range o f standards (0.001-10 mU/1). 
The sets o f standards were assayed using antibody G2 coated microtitre plates 
overcoated with casein and using TMB substrate. The standard curves produced were 
compared with the equivalent buffer standard curve in order to assess the application of 
the assay in a urine matrix (Figure 3.3.1). Although both the neat urine and the diluted
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urine standards show linearity with the buffer standards, there is a considerable matrix 
problem which requires further investigation.
3.3.2 Recovery of human growth hormone in urine
A urine sample was serially diluted in assay buffer and growth hormone standard 
added. The diluted urine was then assayed. The absorbance produced in the assay for 
each sample relative to a buffer standard is shown (Figure 3.3.2). Clearly there is an 
interfering substance present in urine which dilutes out in buffer.
3.3.3 The effects of the urine matrix on the assay
An early morning urine sample was divided into two aliquots and one was dialysed 
overnight into plate assay buffer. Standard curves were prepared by diluting growth 
hormone UK 9 standard in plate assay buffer, urine, and dialysed urine. The standards 
were assayed to determine if  the matrix effects present in urine could be removed by 
dialysing the urine into buffer.
Duplicate standard curves were prepared in urine, buffer and dialysed urine and 
assayed using either TMB (Figure 3.3.3) or HPPA substrate (Figure 3.3.4) These are 
shown with both linear and with log Y axes (Figure 3.3.5, Figure 3.3.6a). 
Fluorescence assay standard curves were prepared using Labsystems G2 (Figure 
3.3.6a), NUNC G2 (Figure 3.3.6b), and NUNC G3 coated plates (Figure 3.3.6c).
The urine standard curves showed a marked effect on the binding o f the standards 
whereas the dialysed urine showed binding which was intermediate between the urine 
and the buffer standards which indicated that although dialysis did reduce the matrix 
effect it did not entirely remove it. The matrix effects may also vary from sample to
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sample depending on whether they are 24 hour samples or early morning samples and 
depending on the concentrating ability o f the particular patient's kidneys.
3.3.4 Dilution of urine from an acromegalic subject
A urine sample was obtained from a known untreated acromegalic patient. This sample 
was split into two aliquots and one was dialysed overnight. A series o f dilutions of the 
dialysed and undialysed urines were produced and the urines were then assayed using 
HPPA substrate. A buffer standard curve was also prepared for comparison. NUNC  
G2 (Figure 3.3.7 a), NUNC G3 (Figure 3.3.7 b), and Labsystems G2 coated plates 
(Figure 3.3.7 c) were used and all showed similar parallelism o f the diluted urine with 
the urine standards but in each case the undialysed urine dilutions showed much lower 
binding.
3.3.5 Investigation of the possible presence of a high molecular 
weight interferent
It was thought that the differences in the standard curves obtained when comparing 
standards diluted in urine with standards diluted in buffer and dialysed urine may be 
due to a high molecular weight interferent. In order to attempt to investigate this 
problem the assay was modified and the label and diluted standards were incubated in a 
separate uncoated plate and then transferred to the coated plates. Hence the labelled 
antibody was allowed to bind to the growth hormone before the coated antibody, which 
is the reverse of the conventional assay. The standard curves obtained from this 
modified assay still showed differences between the buffer, urine and dialysed urine 
standards as in the conventional assay (Figure 3.3.8). The binding for the transferred 
assay was much lower than for the conventional assay. This method also lacks a 
washing step between the reagent additions. For these reasons it was decided not to 
proceed further with this assay format.
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C H A PTER  4 D ISC U SSIO N  AND CON CLUSIO NS  
4.1 C onjugate production
The original aim of this project was to develop a fluorescence enzyme immunoassay for 
urinary growth hormone similar to the method reported by Hashida et.al. (1987). A 
large portion of the time was spent attempting to produce an Fab' fragment o f  sheep 
polyclonal antiserum using the method reported by Ishikawa et. al. (1988). This was 
not successful as the F(ab')2 produced could not be further reduced to Fab', perhaps 
because the method was not fully optimised or for other reasons. For example it was 
thought that the F(ab')2 may have been resistant to reduction by mercaptoethylamine 
and therefore mercaptoethanol and thiomersal were examined as alternatives, without 
success. There was also the possibility that the pepsin digestion left the F(ab')2 in a 
form which could not be further reduced or that the particular isotype of IgG was 
simply pepsin resistant. Alternatively there was the possibility that it may not in fact be 
F(ab')2 which had been produced, but this was unlikely since some initial work to 
verify the binding of the fragment to growth hormone after pepsin digestion, using 
radiolabeling methods, showed binding of the F(ab')2 to growth hormone.
Following a successful attempt to produce Fab' by a kit method marketed by Bioprobe 
International Incorporated, the Ishikawa method was abandoned and a conjugate of 
Fab' and peroxidase was produced using the maleimide method. The recovery of 
peroxidase-maleimide conjugate was not entirely satisfactory and some work requires 
to be done if this method is to be used in the future. Since an adequate supply of 
peroxidase label was produced to complete this project, and time was limited, 
optimization was considered unnecessary.
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4.2 ELISA developm ent
The original method published by Hashida et. al. (1987) utilised 3 millimetre 
polystyrene beads as the separation system to which the monoclonal antibody was 
coated by simple adsorption. Some initial experiments showed no particular advantage 
of this method over plastic microtitration plates, although in theory the large surface 
area of the beads may allow coating of more protein than the wells of the plates. The 
major disadvantage of the beads was that there was no available automated colourimeter 
or fluorimeter which could adequately detect the colour or fluorescence produced by the 
enzyme reaction and so it was decided to concentrate efforts on the development of a 
plate assay but to retain the use of beads as a possible alternative. It is also possible to 
attach the monoclonal antibody to microparticles for use in a fluorescence or a 
luminescence system such as the Abbott IMX system but these were outwith the scope 
of this project. Alternatively an Fab' fragment can be attached covalently to plastic 
surfaces using maleimide linking reagents which ensures that the fragment is correctly 
orientated on the surface to allow antigen binding.
Once the peroxidase conjugate was produced the initial assays performed using OPD 
substrate provided such a small colour change that the project was almost abandoned. 
However some alternative substrates, namely ABTS and TMB, provided a far greater 
colour change. This allowed initial optimization of an ELISA method to be carried out 
and some work investigating problems such as the high blank values, light effects and 
edge effects was performed. It was later discovered that these were not uncommon 
problems with plate assays and require considerable time and effort for optimization. 
Many of the assays performed appeared to have higher binding in the wells at the ends 
of the strips so that for example the zero standard in the A l position was often higher 
than the first standard in the A2 position. The experiments which were carried out in 
order to confirm this, initially showed a slight edge effect when themean absorbances 
were calculated for each of the strip positions across eight different strips. This
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experiment did not provide the same effect when it was repeated a second time. Edge 
effects can be due to a combination of three factors. Firstly, there can be uneven 
distribution of light to the different well positions. This effect was minimised by 
incubating the plates in the dark during the enzyme reaction following the observation 
that the surplus TMB substrate solution developed a slight blue colour during the 
incubation period. As an additional precaution the substrate was made up fresh 
immediately before use. Secondly, edge effects can be due to variations in the drying 
of the protein on the plate between steps, and in particular, between washing and 
addition of substrate, excessive drying leads to loss of enzyme activity. This effect was 
minimised by addition of substrate as soon as was possible after washing the plates. 
There is evidence that washing is the most critical step in achieving assay precision and 
that it is essential that no remnants of the wash solution remain as even tiny amounts of 
wash solution can lead to significant suppression of colour development. Attempts 
were made to ensure the complete removal of the wash solution by ‘bashing’ the plates 
onto paper towels, but this was less than satisfactory. An alternative method was to 
use a manual aspirator to remove the remaining liquid. A related problem is that of 
vacuum control of the aspirator on automated washers, where too low a vacuum 
pressure causes incomplete drying of the wells while too high a vacuum leads over 
drying and to loss of enzyme activity. There may also be considerable variability in the 
aspiration from one nozzle to the next. Thirdly, edge effects can be caused by 
temperature gradients across the plate which lead to differences in binding and in colour 
development. Many commercial systems now use specially designed incubators which 
maintain the temperature across the plates to within very tight limits of around 0.2 °C, 
with negligible variation from well to well. Unfortunately this equipment was not 
available at the time.
Another recurring problem was that of outliers which were wells with unexpectedly 
large colour changes. This may be due to problems with the plate coating or washing 
or due to contamination during the assay. Great care was required to prevent
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contamination from one well to another. One source of possible contamination which 
was discovered was the dispensing head of the plate washer, which was not adjusted 
for height correctly, and tracked across the meniscus of the liquid in the wells when 
returning from the last strip to the first. The plate shaker speed had to be set fast 
enough to allow proper mixing but prevent splashing. Finding a suitable dispensing 
device for the ELISA reagent addition was difficult since it had to be precice, accurate, 
fast enough to prevent excessive variation in incubation times but should not eject the 
liquid so fast that it squirted the liquid back out of the wells. Several models were used 
and all were found to have limitations. Outliers can also be caused by variation in the 
amounts of wash solution added to each well, caused by salt deposits on the dispenser 
nozzles or due to air bubbles which become trapped in the wash tubing and when 
dislodged result in addition of insufficient wash solution to some wells. These 
problems can only be prevented by scrupulous maintenance of the plate washers and 
careful priming of the wash solution. The wash solution was always primed through 
several times before use to prevent contamination from the wash solutions o f  other 
users which may contain azide, which is reported to reduce peroxidase activity 
(Ishikawa et. al 1983).
Variation in the coating of wells is a perpetual problem in plate assays and careful 
maintenance of coating temperatures and drying are essential. It is desirable that the 
coated protein should form a monolayer on the surface of the well since multilayers are 
unstable and can interfere with the assay by causing protein-protein interactions. Hence 
it is necessary to carefully optimise the protein and overcoating concentrations for the 
assay. Some commercial kit manufacturers dry the plates by centrifugation to ensure 
consistent drying. In addition commercial companies coat plates in large batches and 
carry out quality control tests of the coating efficiency on sample plates from each 
batch. In the method used here the plates were washed in saline between coating steps 
and stored with moist filter paper in sealed bags. Storage of coated plates would have 
to be further investigated if the assay were to be used routinely.
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Initially lyophilised bovine albumin was used as an over-coating or blocking reagent to 
reduce non-specific binding to the wells. Following advice that casein or non-fat dried 
milk solution could provide lower non-specific binding than BSA, some comparisons 
were earned out (Livesey and Donald 1982). From these comparisons there appeared 
to be a small improvement in the non-specific binding on using the dried milk blocking 
reagent and this was adopted in the later assays.
The TMB supplied by sigma did not entirely dissolve in buffer, therefore it was 
centrifuged briefly before use to remove the remaining undissolved material.
4.3 FEIA developm ent
It was always the intention to develop an assay which used a fluorescence substrate 
since the reports of Ishikawa claimed that this allowed sufficient sensitivity to measure 
urinary growth hormone. Unfortunately no equipment was available locally which 
could adequtely measure the fluorescence of HPPA. It was not until limited use of a 
fluorescence platereader was arranged by Labsystems UK and Labsystems Finland that 
the FEIA assay could be investigated. This work showed that the use of HPPA 
provided a wider working range than TMB but there was no gain in sensitivity due to 
high background readings from the substrate, probably due to impurities. These 
conclusions agree with the findings of Tuuminen et. al. (1991). Purification of the 
substrate is apparently not easily achieved, and the substrate which was recrystallised in 
house provided no improvement in background signal. (Imagawa et. al. 1983), 
(Hashida et. al. 1983) In addition there appears to be considerable batch to batch 
variation in the purity of the substrate. Sigma now supplies HPPA in tablet form which 
may be of higher purity than the crystalline product available originally and which is 
more convenient to use. HPPA is available from an alternative Japanese supplier but 
the cost prohibits its use. There are fluorescence substrates available for other enzymes 
which in theory may provide better sensitivity than HPPA and luminescence substrates 
are also available which may also allow lower sensitivity (Zaitsu 1980).
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4.4 Enhanced L um inescence Assay
Following the completion of the practical part of this project a luminescence platereader 
and an enhanced luminescence substrate became available for limited use. Standard 
curves were set up as previously and these showed a far wider measuring range and 
lower detection limit (0.001 mU/1) than that obtained using TMB or HPPA substrates. 
This is very encouraging, but unfortunately there was not any opportunity to optimise 
the method and the assay simply followed the protocol for the Kodak Diagnostics 
Amerlite TSH 30 assay from which the substrate was obtained. It is likely that the use 
of this or a similar substrate could lead to a useful working urine growth hormone 
assay.
4.5 U rine assay
Several experiments were carried out to examine the matrix effects of urine on the 
assay. In many of the reported assays urine is pretreated by dialysis into assay buffer 
to prevent interference from the wide variations in salt concentrations present in the 
matrix of urine. Ideally urine samples could be added to the wells of the plates and 
incubated with the coated antibody, but as demonstrated (Figure 3.3.3) there is 
considerable difference between the binding of the urine standards and buffer 
standards. Two options were available, the first being a sample dilution in buffer 
which would help to standardise the pH and reduce the salt concentration, this 
unfortunately would also reduce the amount of growth hormone present and therefore 
also reduces the potential sensitivity of the system. Secondly pre-dialysis of the sample 
was considered and the results showed this to be effective in reducing the effects of the 
interference although there was still a residual effect on the binding. It is possible that 
the dialysis was simply incomplete or that there was a high molecular weight interferent 
present. An attempt was made to investigate the presence of this interferent but this was 
not particularly successful and requires some further investigation . Although in theory 
dialysis is tedious to perform there are systems available to improve upon the use of
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dialysis tubing when handling large numbers of samples or, alternatively, the use of 
extraction columns may be worth examination.
4.6 R ecent developm ents
A urine growth hormone method has been published by Turner et. al. (1993) using an 
immunochemiluminometric assay (ICMA). The assay uses a sheep polyclonal anti 
growth hormone antibody coated to tubes and a monoclonal antibody labeled with an 
acridinium ester. The antibodies were produced by the Institute of Biochemisty, 
Glasgow Royal Infirmary and the Scottish Antibody Production Unit and are the same 
as those used in this project. This assay is reported to have a detection limit of 1.1 
mU/L. The method requires dialysis of urine samples to prevent interference from urea 
and NaCl which, as their concentrations increased, were shown to lead to a reduction in 
growth hormone recovery. The clinical studies showed good correlation between 
serum and urine growth hormone concentrations in healthy volunteers, who were given 
intravenous growth hormone, and in patients with acromegaly. The study also 
examined pre-pubertal children of normal and short stature and showed that the short 
stature children excreted less growth hormone and grew at a slower rate than the normal 
stature children. Considerable intra-individual variation was found in growth hormone 
secretion and the authors recommended that sequential urine growth hormone analyses 
should be performed, and the results interpreted in conjunction with growth velocity 
measurements. The authors also recommended further examination of the pattern of 
renal excretion of growth hormone. Alternatives to dialysis, were examined as it was 
found cumbersome to perform, these included using ethyl or cyano bonded cartridges 
but the recoveries obtained were around 50% as compared to 85-90% for dialysis. The 
team also found it was necessary to add albumin to the dialysis buffer to prevent 
growth hormone adhering to the dialysis tubing.
This method provides a useful comparison since the antibodies used were the same as 
those used in this project but the labeling technique was different and it is evident that
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the use of acridinium esters provides a very sensitive labeling system. The success of 
this method is encouraging since it shows that the antibodies are capable of providing 
the required sensitivity provided the labeling is adequate and it may be possible to 
produce a suitable assay in the future.
4.7 Final conclusions
There are a number of future possibilities which may be explored in order to produce a 
viable urinary growth hormone assay. The best available pair of matched antibodies, 
which may be in the form of antibody fragments or genetically altered antibodies, is the 
essential basis of a sensitive assay and if they are carefully chosen may limit cross 
reaction from other hormones. A highly sensitive label is required and this may be an 
enzyme using a luminescence substrate similar to that used by Kodak Diagnostics 
Limited or alternatively it may be a fluorescence substrate such as Attophos, an alkaline 
phosphatase substrate which is reported to be highly sensitive. (Attophos Product 
Information Bulletin 1991) The separation system may be based on microparticles as in 
the Abbott IMX system, or may be an automated plate processing system such as that 
marketed by Kodak Diagostics Ltd. where all the reagent addition steps, washing steps 
and incubation temperatures are carefully controlled within a purpose built analyser. 
Automation may provide a useful improvement in precision and ensure that the batch to 
batch assay conditions are identical, essential in an assay such as this which requires 
the limits of sensitivity to be stretched.
The problem of the interference from the matrix of urine also requires to be addressed 
in order to identify if NaCl, urea and glucose are responsible, or some other urine 
component (Moreira-Andres et. al. 1993), (Baumann and Abramson 1983). Dialysis 
of the urine does not entirely remove this interference therefore it may in part may be 
due to a large molecule which prevents the binding of growth hormone to the antibody 
binding sites by steric hindrance or by binding to growth hormone itself alters its ability 
to bind to the antibody.
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It may be that the role of urine growth hormone measurement in the future will be as a 
non invasive screening method for assessing growth hormone secretion and the 
replacement dose in growth hormone treatment for growth hormone deficiency but it 
may be less useful in mild forms of growth hormone insufficiency (Moreira-Andres et. 
al. 1993).
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